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Summary 
 
Cancer stem cells (CSC) are poorly differentiated, slowly proliferating cells, with high 
tumorigenic potential. Some of these cells, as it has been shown in leukemia, evade chemo- 
and radiotherapy and recapitulate the tumor composed of CSC and their highly proliferative 
progeny. Therefore, understanding the molecular biology of those cells is crucial for 
improvement of currently used anti-cancer therapies. 
 This work is composed of two CSC-related projects. The first deals with CD44, a 
frequently used marker of CSC; the second involves Imp2 and its role in CSC bioenergetics. 
PART 1. CD44 is a multifunctional transmembrane protein involved in migration, homing, 
adhesion, proliferation and survival. It is overexpressed in many cancers and its levels are 
correlated with poor prognosis. CD44 is also highly expressed by CSC and in many 
malignancies it is used for CSC isolation.  
 In the present work full-lenght CD44 nuclear localization was studied, including the 
mechanism of nuclear translocation and its functional role in the nucleus. Full-length CD44 
can be found in nuclei of various cell types, regardless of their tumorigenic potential. For 
nuclear localization, CD44 needs to be first inserted into the cell membrane, from which it is 
transported via the endocytic pathway. Upon binding to transportin1 it is translocated to the 
nucleus. The nuclear localization signal recognized by transportin1 has been determined as 
the first 20 amino acids of the membrane proximal intracellular domain.  Nuclear export of 
CD44 is facilitated by exportin Crm1. Investigation of the function of nuclear CD44 revealed 
its implication in de novo RNA synthesis. 
PART 2. Glioblastoma multiforme is the most aggressive and most frequent brain 
malignancy. It was one of the first solid tumors from which CSC have been isolated. Based on 
the similarity between GBM CSC and normal stem cells expression of an oncofetal mRNA 
binding protein Imp2 has been investigated.  
 Imp2 is absent in normal brain as well as in low grade gliomas, but is expressed in 
over 75% GBM cases and its expression is higher in CSC compared to their more 
differentiated counterparts. Analysis of mRNA transcripts bound by Imp2 and its protein 
interactors revealed that in GBM CSC Imp2 may be implicated in mitochondrial metabolism. 
Indeed, shRNA mediated silencing of protein expression led to decreased mitochondrial 
activity, decreased oxygen consumption and decreased activity of respiratory chain protein 
complex I. Moreover, lack of Imp2 severely affected self-renewal and tumorigenicity of GBM 
CSC. Experimental evidence suggest that GBM CSC depend on mitochondrial oxidative 
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phosphorylation as an energy producing pathway and that Imp2 is a novel regulator of this 
pathway. 
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Résumé 
 
Les cellules cancéreuses souches sont des cellules peu différentiées, à proliferation 
lente et hautement tumorigénique. Ces cellules sont radio-chimio résistantes et sont capable 
reformer la tumeur dans sont intégralité, reproduisant l’hétérogénéité cellulaire présent dans la 
tumeur d’origine. Pour améliorer les therapies antitumorales actuelles il est crucial de 
comprendre les mécanismes moléculaires qui caractérisent cette sous-population de cellules 
hautement malignes. 
Ce travail de thèse se compose de deux projets s’articulant autour du même axe : 
Le CD44 est une protéine multifonctionnelle et transmembranaire très souvent utilisée 
comme marqueur de cellules souches tumorales dans différents cancers. Elle est impliquée 
dans la migration, l’adhésion, la prolifération et la survie des cellules. Lors de ce travail de 
recherche, nous nous sommes intéressés à la localisation cellulaire du CD44, ainsi qu’aux 
mécanismes permettant sa translocation nucléaire. En effet, bien que principalement décrit 
comme un récepteur de surface transmembranaire, le CD44 sous sa forme entière, non clivée 
en peptides, peut également être observé à l’intérieur du noyau de diverses cellules, quel que 
soit leur potentiel tumorigénique. Pour passer ainsi d’un compartiment cellulaire à un autre, le 
CD44 doit d’abord être inséré dans la membrane plasmique, d’où il est transporté par 
endocytose jusqu’à l’intérieur du cytoplasme. La transportin1 permet ensuite la translocation 
nucléaire du CD44 via une « séquence signal » contenue dans les 20 acides aminés du 
domaine cytoplasmique qui bordent la membrane. A l’inverse, le CD44 est exporté du noyau 
grâce à l’exportin Crm1. En plus des mécanismes décrits ci-dessus, cette étude a également 
mis en évidence l’implication du CD44 dans la synthèse des ARN, d’où sa présence dans le 
noyau. 
Le glioblastome est la plus maligne et la plus fréquente des tumeurs cérébrales. Dans 
ce second projet de recherche, le rôle de IMP2 dans les cellules souches tumorales de 
glioblastomes a été étudié. La présence de cette protéine oncofoetale a d’abord été mise en 
évidence dans 75% des cas les plus agressifs des gliomes (grade IV, appelés glioblastomes), 
tandis qu’elle n’est pas exprimée dans les grades I à III de ces tumeurs, ni dans le cerveau sain. 
De plus, IMP2 est apparue comme étant davantage exprimée dans les cellules souches 
tumorales que dans les cellules déjà différenciées. La baisse de l’expression de IMP2 au 
moyen de shRNA a résulté en une diminution de l’activité mitochondriale, en une réduction 
de la consommation d’oxygène ainsi qu’en une baisse de l’activité du complexe respiratoire I. 
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L’inhibition de IMP2 a également affecté la capacité de renouvellement de la population des 
cellules souches tumorales ainsi que leur aptitude à former des tumeurs. 
Lors de ce travail de thèse, une nouvelle fonction d’un marqueur de cellules souches 
tumorales a été mise en évidence, ainsi qu’un lien important entre la bioénergétique de ces 
cellules et l’expression d’une protéine oncofoetale. 
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General introduction 
 
Cancer is a disease of abnormal cellular proliferation leading to tumor formation. Cells 
undergo malignant transformation as a result of various mutations, which allow them to evade 
regulatory mechanisms that constrain normal tissues from excessive proliferation. During 
tumor progression cancer cells acquire several biological features that change their physiology 
and sustain cancer growth – self-dependence on growth signaling, resistance to growth-
inhibitory signals, escape from programmed cell death, unlimited replicative capability, 
activation of angiogenic signaling, tissue invasion and metastasis [1]. These cancer hallmarks 
are often underlined by genetic alterations in two classes of genes – oncogenes and tumor 
suppressor genes. Mutations in oncogenes, such as RAS and MYC, deregulate pathways 
leading to enhanced cell proliferation and distorted expression of tumor-suppressors, as p53 or 
Rb, provides a means to escape from proliferation control. Although it seems that all cancer 
types need to sustain growth and survival of tumor cells, various combinations of molecular 
dysfunctions can lead to the same outcome due to the complexity and redundancy of cellular 
signaling networks. This heterogeneity of molecular causes of malignant transformation in 
different tumors is one of the reasons for low efficiency of current therapies.  
Although cancers can be characterized by distinct molecular features, their behavior, 
described as hallmarks of cancer, remains the same. Thus, the design of first cancer therapies 
focused on a feature common to most cancers – proliferation – and was directed to kill the 
rapidly dividing tumor cells. However, this approach was assuming homogeneity of a given 
tumor – equal proliferating capacity of all the cells within the tumor mass. As early as in the 
1930s it had become clear, that tumors are heterogenous [2]. Cells within a tumor can differ in 
their morphology, but also in their proliferative capacity and the ability to recapitulate a tumor 
upon injection into immunocompromised animals [2, 3].  
The heterogeneity of cancer cells within a tumor can be explained by one of the 
following models (Fig.1) [3]. The stochastic model assumes that cancer cells are biologically 
equal and that they are equally sensitive to intrinsic or extrinsic factors. Those factors, such as 
active cellular signaling pathways or signaling initiated by the tumor microenvironment, are 
unpredictable and they vary within a given tumor, creating cancer cell heterogeneity. The 
second model assumes that tumors resemble perturbed normal tissues, which are organized in 
a hierarchical manner, with slowly dividing, self-renewing stem cells that give rise to a highly 
proliferative cell population. Both models account for the fact that only a subset of cells has a 
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tumor initiating capacity. The difference lies in the origin of this feature. In the stochastic 
model every cell within a tumor can potentially acquire this phenotype, so the tumor initiating 
potential depends on intrinsic or extrinsic factors. In contrast, in the hierarchical model there 
is only a subset of cells possessing unique biological properties that allow them to initiate 
tumor growth. 
 
 
Figure 1. Comparison of hierarchical and stochastic models of cancer [3] 
 
Leukemia was the first cancer type in which the cell heterogeneity was observed [3]. 
The first proof of hierarchical organization of cancer cells also came from leukemia, were 
cancer stem cells (CSC) were discovered [4, 5]. More recently CSC were isolated from many 
solid tumors, including brain, breast and colon cancer [6-9]. Those discoveries support the 
model of cancer in which slowly proliferating cancer stem cells give rise to bulk tumor cells 
of high but limited proliferative capacity. In this regard CSC share some features with normal 
tissue stem cells: through asymmetric cell division they give rise to both stem cells and more 
differentiated cell and are thereby able to renew the stem cell pool and to produce more 
proliferative progeny; upon injection into immunocompromised mice CSC initiate tumor 
formation, in which both CSC and their differentiated progeny are present. The similarity of 
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CSC to normal stem cells is also reflected in their gene expression profiles [10], which is 
responsible for frequently observed protein expression similarity between these cell types. For 
instance, multidrug transporters of the ABC-cassette family can be found both in CSC and 
normal stem cells, providing protection of stem cells from cytotoxic agents and, in the case of 
CSC, rendering them resistant to chemotherapy. Convergent expression of stem cell 
associated proteins by CSC does not necessarily mean that CSC arise from normal stem cells 
undergoing malignant transformation. It is also possible that they are derived from more 
committed cells in a process of de-differentiation. Whatever the origin of CSC, it seems likely 
that their presence in a multitude of cancers is responsible for disease relapse, as they respond 
poorly to chemo- or radiotherapy. Therefore, for therapeutic purposes it is important to better 
understand the molecular mechanisms governing CSC. 
Expression of various cell surface proteins was used to isolate CSC from solid tumors 
(Table 1). One of the first markers, shown to discriminate between CSC and differentiated 
cancer cells was CD44 [11]. In breast cancer its presence combined with absence of CD24 
was shown to select for cells able to recapitulate a phenocopy of the original tumor upon 
xenotransplantation [7]. Cells isolated from primary prostate tumors or metastases that 
express CD44, but also high levels of integrin 2 1 and CD133, had increased tumorigenic 
potential in vitro [12]. In ovarian cancer CSC have been identified by CD44 and CD117 
expression [13].  
The panel of CSC markers is growing, but controversies have arisen around the use of 
some of them. Isolation of CSC based on CD133 expression has yielded contradicting results, 
as several groups have shown that CD133
-
 cells can also be tumorigenic [2]. The tumorigenic 
potential of CD133
+
 cells could be cancer type specific, but the use of different antibodies for 
the same marker in CSC isolation protocols can also be the cause of the opposing results. The 
use of cell surface markers for CSC isolation has also been questioned because their 
expression is not constant. Thus, the above mentioned CD133 expression can be modulated 
by hypoxia [14]. Other CSC markers seem to be specific only for certain cancer types, like 
ABCB5 and ABCG2, used in melanoma CSC isolation, which do not distinguish CSC 
populations in colon, breast and prostate cancer [2]. Moreover, combinations of different 
markers and their increasing numbers render it more difficult to find a unified protocol for 
CSC isolation.  
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Tumor type CSC marker 
Tumor cells 
expressing CSC 
marker (%) 
Minimal number of 
cells expressing CSC 
markers for tumor 
formation 
Breast CD44
+
/CD24
-/low
 11 - 35 200 
Breast CD44
+
/CD24
-
 ND 2000 
Breast ALDH1
+ 
3 - 10 500 
Brain CD133
+
 (GBM) 
CD133
+
 (MB) 
19 - 29 
6 - 21 
100 
100 
Brain CD133
+ 
2 - 3 500 
Colon CD133
+
 1.8 - 25 200 
Colon CD133
+
 0.7 - 6 3000 
Colon EpCAM
hi
/CD44
+ 
0.03 - 38 200 
Head and neck CD44
+ 
0.1 - 42 5000 
Pancreas CD44
+
/CD24
+
/ESA
+ 
0.2 - 0.8 100 
Pancreas CD133
+
 1 - 3 500 
Lung CD133
+
 0.32 - 22 10000 
Liver CD90
+ 
0.03 - 6 5000 
Melanoma ABCB5
+ 
1.6 - 20 1000000 
Mesenchymal Side population (Hoechst dye) 0.07 - 10 100 
 
Table 1. Prospective isolation of human CSC from freshly dissociated solid tumors; ALDH – aldehyde 
dehydrogenase; EpCAM – epithelial cell adhesion molecule; ESA – epithelial specific antigen; GBM – 
glioblastoma multiforme; MB – medulloblastoma; ND – not determined; modified from [15] 
 
Another way for CSC isolation is the dye exclusion assay. This assay is based on the 
expression of ABC transporters on putative CSC. Upon staining with Hoechst 33342 the ABC 
transporters pump the dye out of the cell, creating Hoechst negative side populations (SP) 
containing CSC. SP based isolation of CSC has been used in glioblastoma, melanoma, in 
breast and lung cancers [16]. However, contradicting results came from subsequent studies on 
thyroid, adrenocortical and glioma CSC, showing that non-SP cells can generate SP cells and 
that they are equally proliferative and tumorigenic [17-19]. Furthermore, SP size has been 
shown to depend on density of cell culture and Hoechst concentration [2] and the mutagenic 
and carcinogenic potential of the dye renders it less reliable for CSC isolation. 
The debate over the use of different methods for CSC isolation remains open. 
However, increasing numbers of stem cell markers allow studying the best possible 
combinations specific for CSC from different cancer types. Yet, the most reliable markers 
would be the cell surface proteins specifically expressed by CSC and at the same time playing 
a vital role in CSC biology. Thus, it is crucial to decipher the functional relevance of those 
proteins in CSC. Further characterization of the molecular pathways governed by the stem 
cell markers is also necessary for developing CSC-targeted therapy. 
This thesis is composed of two CSC-related projects. The first aims at identifying new 
biological features of the CSC marker CD44 and was described in the article “Transportin 
regulates nuclear import of CD44” published on October 1st 2010 in the Journal of Biological 
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Chemistry. The second project investigates the role of the oncofetal protein Imp2 in 
glioblastoma cancer stem cells, resulting in a manuscript entitled “Oxidative phosphorylation 
regulated by Imp2 is crucial for glioblastoma cancer stem cells”. 
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PART 1: Nuclear translocation of CD44 
Introduction 
 
Before CD44 had been associated with cancer stem cells, it had been extensively 
studied in various cellular contexts. First, it was demonstrated to be cell surface extracellular 
matrix receptor [20]. Its expression has been observed in most normal tissues [21], yet higher 
levels of CD44 and its splicing variants correlate with cancer progression and metastasis [22]. 
Association of CD44 with metastasis and the cancer stem cell phenotype has renewed interest 
in its molecular functions. 
The CD44 protein is encoded by a gene that comprises 20 exons [23]. The most 
abundant form of CD44 is derived from a transcript containing exons 1-5, 16-18 and 20. This 
standard form of CD44 (CD44s) is translated into a 341aminoacid (aa) molecule that can be 
divided into three domains: a N-terminal extracellular domain (248aa), a transmembrane 
domain (23aa) and a C-treminal cytoplasmic domain (70aa). Due to cell context dependent N- 
and O-glycosylation of its extracellular domain the molecular size of CD44s can vary. Taking 
into account all the possible splicing variants and glycosylation combinations over 800 
isoforms of CD44 could be generated, yet not all variants are expressed [22]. 
The principal function of CD44 is binding to hyaluronic acid (HA), an important 
component of the extracellular matrix (ECM) [20]. Binding of HA is crucial for CD44 
mediated motility and can be modulated by intracellular signaling as well as CD44 
ectodomain cleavage [24]. In addition to HA binding CD44 can activate integrins, modulating 
cellular adhesion [23]. Another function of CD44 is assembling MMP7 and MMP9 with their 
substrates on cell surface. Only when bound by CD44, can MMP9 activate TGF-β, which 
triggers neovascularization [25]. Similarly, binding of MMP7 to CD44 allows it to cleave 
heparin-binding epidermal growth factor, which also upon interaction with CD44 activates 
pro-survival signaling [26].Those interactions can be further enhanced by CD44-ERBB4 
complexing [26]. It is the ectodomain of CD44 that mediates these interactions. However, the 
intracellular part of the HA receptor is also biologically active. Via interaction with ezrin, 
radixin and moesin (ERM) proteins and Merlin, CD44 is linked to actin cytoskeleton, 
influencing local cytoskeletal reorganization, as well as CD44-mediated Ras signaling [23, 
27]. ERM proteins also mediate CD44 control over the Hippo pathway linked to stress 
induced apoptosis [28]. Moreover, the intra-membrane cleavage of CD44 can release the 
intracellular domain, which is translocated to the nucleus and activates gene transcription [29]. 
The broad spectrum of CD44 protein interactions makes it an important player in various 
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cellular processes. Those distinct functions are orchestrated by different isoforms of CD44, 
generated by mRNA splicing and glycosylation. Since so many isoforms of CD44 can be 
present in different cell types, it is possible that there are still many functions of this protein to 
be uncovered. 
Intracellular signaling mediated by CD44 has primarily mitogenic and anti-apoptotic 
effects. Yet, the main biological process in which CD44 is involved is adhesion. By binding 
to extracellular matrix components and mediating interactions with integrins and ERM 
proteins, CD44 controls cytoskeleton remodeling, influencing cell shape and motility. Thus, it 
is crucial for events such as wound healing, lymphocyte homing, but also normal embryonic 
development and invasion of cancer cells [23]. Overexpression of CD44 can be highly 
advantageous for cancer cells, as it allows them to migrate, increases their proliferation by 
Ras signaling and inhibits apoptosis by interacting with and activating receptor tyrosine 
kinases. 
High expression of CD44 has been used to isolate CSC from hematopoietic and solid 
malignancies, including breast, prostate and colon cancer [11]. The frequency of CD44 
expression in CSC from different tumors reflects its functional importance in those cells. 
Leukemia stem cells secrete HA, that stimulates their homing to the endosteal niche where 
normal hematopoietic stem cells also reside [30]. Expression of CD44 on both cell types is 
crucial for their homing [31], but also for CXCL12-dependent transendothelial migration, that 
facilitates engraftment in the niche [30]. Cancer stem cell niches in solid tumors are not yet 
well studied. Nevertheless, it is possible that the adhesive function of CD44 enables the 
interplay between solid tumor stem cells and their microenvironment. However, in breast 
cancer the HA-CD44 interaction seems to regulate epithelial-to-mesenchymal transition 
(EMT), rather than interaction with the CSC niche [11]. There have also been reports of CD44 
and its variants governing expression of genes associated with stemness, including NANOG 
and MDR1 (also important for multidrug resistance of CSC)[32] and CD44 being a target of 
the stem cell signaling pathway Wnt [33]. Therefore, despite the fact that CSC can be isolated 
from different tumor types with the same marker, the functions that this molecule plays might 
still remain cell-specific. 
At least part of the signal transduction governed by CD44 upon ligand binding is 
conducted through receptor internalization. A fraction of internalized receptor undergoes 
proteolytic cleavage, which generates the intracellular domain (ICD) (Fig.2) [24, 34]. The 
ICD is then translocated to the nucleus where it participates in regulation of gene transcription 
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[29]. However, in our laboratory an observation was made, that also a full-length CD44 
protein could be found in the nucleus. 
The aim of this project was to validate the nuclear localization of full-length CD44, to 
study the mechanism of its translocation and to find its putative function. 
 
 
 
Figure 2. CD44 sequential cleavage [24] 
 
 
Results summary 
 
Using an antibody that recognizes the extracellular domain of CD44 an 
immunofluorescent staining was performed on several cell lines. Clear nuclear staining was 
observed in all tested cell lines, regardless of the tumor type or tumorigenicity. Since the 
antibody used in this assay does not discriminate between cleaved and full-length form of 
CD44, immmunoprecipitation of CD44 was performed, using the nuclear fraction of human 
osteosarcoma cells MNNG/HOS, that endogenously express large amounts of the standard 
form of CD44. This experiment confirmed the presence of full-length CD44 in the nucleus. 
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Figure 3. Nuclear localization of CD44; immunofluorescence staining of CD44 in the 
indicated cell types; nuclei stained with DAPI; 
 
To determine whether nuclear localization is a result of HA receptor internalization 
from the cellular membrane or if de novo synthesized CD44 is translocated directly from the 
cytoplasm, CD44 immunoprecipitation from nuclear extracts was preceded by cell surface 
biotinylation. Detection using streptavidin revealed that the precipitated CD44 band was also 
highly biotinylated, confirming membrane origin of nuclear-localized receptor. This result 
was later confirmed by endocytic pathway inhibition using nocodazole, that resulted in a 
decrease in nuclear staining of the HA receptor. Moreover, overexpression of a mutant CD44 
that lacks signal peptide, necessary for its membrane localization, showed lower level of 
nuclear localization of the protein, underlining the importance of membrane localization for 
nuclear translocation. 
In search for potential protein partners of CD44 which could provide insight into the 
mechanism of its nuclear translocation and its intracellular signaling, a pull-down assay was 
performed. In this assay a large scale immunoprecipitation of CD44 from the cytoplasmic 
fraction was followed by mass-spectrometry analysis. As a result, several proteins of the 
karyopherin family were identified. The interactions between CD44, importin β, transportin1 
and exportin Crm1 were validated by Western blotting.  
Functional validation of the observed interactions was assessed in nuclear import 
assays. Permeabilized, cytosol depleted cells were incubated with cytosolic fractions devoid 
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of import factor or containing an import inhibitor and the influence of those conditions on 
nuclear CD44 localization was measured (Fig. 4A). Importin β depletion from cytosolic 
extracts used in the assay did not influence CD44 localization. However, addition of 
transportin1 inhibitor, peptide M9M [35], significantly reduced CD44 amount in the nuclei. 
These results suggested that CD44 is imported to the nucleus by transportin1. To investigate 
whether export of the HA receptor is mediated by exportin Crm1, an inhibitor, leptomycin B, 
was added to the cells in culture and CD44 localization was monitored over time (Fig. 4B). 
After 4h of treatment an accumulation of nuclear CD44 was observed, implicating exportin 
Crm1 in its trafficking. 
 
 
Further characterization of nuclear translocation of CD44 required determination of its 
nuclear localization signal (NLS). Since both the full-length CD44 and its ICD can be 
translocated to the nucleus, the potential nuclear localization signal should be present in the 
Figure 4. Nuclear translocation of CD44 
depends on transportin1 and exportin 
Crm1 but not on importin ; A – nuclear 
import assay; nuclear CD44 was 
monitored according to its colocalization 
with DAPI staining; importin  depletion 
has no effect on CD44 nuclear 
localization; transportin1 inhibitor M9M 
peptide fused to maltose binding protein 
(MBP) has the same effect as the nulcear 
pore blocker WGA (P values < 0.005); the 
effect is quantified by Imaris software as 
the percentage of colocalization in the 
region of interest (ROI); 250-300 cells 
analysed per condition; B – Leptomycin B 
(LMB) treatment for 2, 4 and 20h; 4h 
incubation with LMB triggers nuclear 
accumulation of CD44.  
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cytoplasmic domain of the protein. Therefore, three mutants were constructed, each lacking a 
different portion of this domain. One of the mutants, t-20, was lacking the first 20aa of the 
cytoplasmic domain, which shared high similarity with the predicted NLS recognized by 
transportin1 [36]. Both the t-20 and a mutant with the deletion of the whole cytoplasmic 
domain had an impaired nuclear localization. Interestingly, the t-20 mutant CD44 was still 
able to bind transportin1, as revealed by immunoprecipitation.  
  The next issue was the function that full-length CD44 could play in the nucleus. 
Knock-down of CD44 in an osteosarcoma cell line resulted in decrease of de novo RNA 
polymerization, measured by incorporation of bromouridine (BrU) (Fig. 5 A-C). The same 
result was observed in fibroblasts isolated from CD44 knock-out mice (Fig. 5D).  
 
 
 
 
 
 
What is more, the expression of the mutants that did not localize to the nuclei also decreased 
BrU incorporation levels (Fig. 5E-F). The control over RNA polymerization could be 
dependent not only on nuclear localization of CD44, but also on HA binding. This notion is 
Figure 5. Nuclear CD44 
enhances RNA synthesis; A – 
shRNA downregulation of 
CD44 expression; 
Immunofluorescence – B – and 
a colorimetric assay - C – show 
weaker BrU incorporation in 
cells depleted of CD44 
compared to control cells (mean 
of three experiments, P value 
*<0.05); D – A similar effect is 
observed in colorimetric assays 
with CD44-/- mouse fibroblasts 
compared to the wild-type cells 
(mean of three experiments, P 
value <0.05); E - MC CD44t-20 
mutant incorporates less BrU 
that the wild type and the 
CD44t-60 mutant as assessed 
by the colorimetric assay (mean 
of three experiments, t-test 
comparison of mutants to WT - 
P values *<0.05; ANOVA P 
value is 0.005593); F – The role 
of extracellular domain in BrU 
incorporation; representative 
graph of the colorimetric assay; 
lack of the signal peptide (dsp) 
or R41A hyaluronian- binding 
site mutation decreases BrU 
incorporation (representative 
experiment, t-test comparison 
of mutants to WT - P values * 
<0.05; ANOVA P value is 
0.025); 
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supported by the fact that cells expressing a mutant unable to bind HA also had lower levels 
of BrU incorporation, despite the proper nuclear localization of this mutant (Fig. 5F). 
The main findings of this work were: 
 Full-length CD44 can be found in the nucleus 
 Full-length CD44 is translocated from the membrane via endocytic pathway, imported 
to the nucleus by transportin1 and exported by exportin Crm1 
 Identification of nuclear localization signal bound by transportin1 
 Full-length CD44 in the nucleus enhances overall RNA synthesis 
 
Discussion and perspectives 
 
Previously, it has been described that CD44 upon ligand binding undergoes sequential 
trimming by several proteases [34]. The ectodomain cleavage releases soluble CD44, which is 
associated with the metastatic phenotype [34]. Subsequent intramembrane cleavage of CD44 
produces the ICD, which is translocated to the nucleus where it activates gene transcription. 
This shedding of CD44 is crucial for efficient turnover of the protein and for cell migration 
into the extracellular matrix. However, the present work demonstrates that also full-length 
CD44 can be found in the nucleus and that it is important for the RNA polymerization. The 
remaining question is whether the ICD and full-length proteins have redundant functions. 
Generation of ICD can be stimulated by TPA treatment (12-O-tetradecanoylphorbol 13-
acetate) [37], but in the cells used in this work CD44 cleavage was not induced. Therefore, it 
is plausible that in some cells, where generation of ICD is not active, translocation of full-
length CD44 may be preferable.  
The present work focuses on the mechanism by which CD44 is translocated to the 
nucleus. It describes proteins responsible for nuclear trafficking of CD44. Interestingly, the 
mutant of CD44 that lacks the first 20aa of the cytoplasmic tail cannot be imported to the 
nucleus although it still binds to transportin1. This issue can be explained by the properties of 
transportin1. Within the NLS of its cargo, transportin1 recognizes two sites, A – a high 
affinity binding site at the C-terminal part of the NLS and B – at the N-terminus of the NLS, a 
site responsible for conformational changes in transportin1 and dissociation of the cargo in the 
nucleus (Fig. 6) [38]. Site A corresponds to residues DRKPS, which were not deleted in the t-
20 mutant. Therefore, the results obtained with this mutant show that site A of the NLS is 
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sufficient for CD44-transportin1 interaction, but the nuclear translocation cannot occur 
without the CD44 fragment containing the B site. 
 
  
Figure 6.  CD44 contains a transportin1-specific nuclear localization sequence (NLS); predicted 
sequence of transportin1 recognized NLS (upper line) corresponds to sequences present in the 
cytoplasmic domain of CD44; lower panel – the major portion of predicted NLS is deleted in 
CD44t-20 mutant (middle line); the DRKPS fragment corresponds to site A recognized by 
transportin1; the NSRRR(CGQ)KKK fragment corresponds to transportin1 binding site B; 
 
 
It has been previously shown that ICD of CD44 activates gene transcription. Thus, the 
nuclear translocation of the full-length protein could have a similar function. Indeed, 
measuring BrU incorporation into nascent RNA showed its dependence on nuclear 
localization of HA receptor. Interestingly, a mutation in HA binding site disables this function. 
Hyaluronan has been previously found in the nucleus [39], thus it is plausible that nuclear 
delivery of the CD44-HA complex is important for RNA synthesis. The direct interaction of 
CD44 with RNA polymerase was excluded in co-immunoprecipitation attempts, yet an 
indirect mechanism is possible. The analysis of protein interactors of nuclear CD44, based on 
pull-down from the nuclear fraction and mass-spectrometry, revealed several potential 
candidate proteins that could mediate this function, including Arp2/3 and SWI/SNF. Arp2/3 is 
an actin-binding protein, involved in actin filament polymerization and cytoskeleton 
remodeling [40]. However, this protein has also been found in the nucleus where it regulates 
RNA polymerase II-dependent transcription [41]. Both Arp2/3 and CD44 can be linked to 
actin filaments, therefore it would be of interest to know whether the observed effect of CD44 
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on RNA synthesis could also depend on nuclear actin and its interactors. Nuclear SWI/SNF 
complex controls transcription by chromatin remodeling [42]. Interestingly, it has been shown 
that BRG-1 subunit of this complex regulates CD44 expression [43]. Therefore, it could be 
that CD44 creates a feedback loop, controlling its own expression via the SWI/SNF complex. 
Further characterization of the interactions between CD44 and nuclear proteins involved in 
RNA synthesis could reveal new mechanisms and potential new functions of the HA receptor. 
It would be also of interest to investigate whether there are any specific transcripts that are 
increasingly synthesized in the presence of nuclear CD44. 
Another point not discussed in this study is the significance of nuclear CD44 in cancer. 
Although the nuclear localization seemed not to be cell type restricted and did not correlate 
with the metastatic potential of tested cancer cell lines, it might be that nuclear CD44 has 
different targets in different cancer cells. Since its expression is often associated with 
malignant phenotype and cancer stem cells, the nuclear function of full-length CD44 
associated with RNA synthesis may affect pathways important for tumorigenesis. 
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PART 2: Imp2 in glioblastoma stem cells 
Introduction 
 
One of the first discoveries of CSC in solid tumors was the isolation of CD133 
expressing cells from the glial brain tumor, glioblastoma multiforme (GBM) [6]. It has been 
shown that upon xenotransplantation only the CD133+ subpopulation, comprising 19-22% of 
tumor cells, was able to recapitulate the parental tumor, containing both CD133+ and CD133- 
cells. This discovery initiated a wide search for CSC in solid malignancies, with CD133 as 
CSC marker. Several other cell surface proteins have also been shown to enrich CSC 
populations in GBM, including SSEA1[44] and CD44 [45].To avoid the bias from 
heterogeneous protein expression, GBM CSC can also be isolated based on their similarities 
to normal neural progenitor cells. Both the CSC and neural stem cells (NSC) under specific 
culture conditions form neurospheres in vitro. Studies of GBM CSC are therefore a valid 
source of methods used in the CSC field, as CD133 and neurosphere formation are widely 
used in CSC research. 
Glioma is the most common primary brain tumor, diagnosed in 5 per 100000 persons 
each year [46]. Glial tumors can be divided into histological subtypes including astrocytoma, 
oligodendroglioma and mixed oligoastrocytoma. This division is based on histological 
similarities between tumor cells and normal glial cells (astrocytes and oligodendrocytes) [46]. 
Gliomas comprise a spectrum of low to high grade malignancies, where low-grade tumors 
often progress to a higher grade [46]. The most malignant type of glioma is glioblastoma 
multiforme (GBM), accounting for over 51% of all gliomas diagnosed in adults [47]. GBM is 
associated with extremely poor prognosis with median survival of 9-14 months, despite the 
aggressive therapy including surgery, chemotherapy and radiation. 
 At the histopathological level GBM can be described as a tumor of poorly 
differentiated neoplastic astrocytes, with cellular and nuclear atypia and characteristic 
pseudopallisading necrosis [46]. Yet, within a given tumor major heterogeneity is often 
observed, particularly regarding expression patterns of transcriptional regulators, tumor-
suppressor proteins and kinase mutations [48]. Different entities of a tumor correspond to a 
divergent clonal expansion of tumorigenic cells. These observations raised the question of the 
cell of origin of GBM. Initially, it was thought that GBM originates from astrocytes. However, 
the first step of transformation requires cells to proliferate whereas in adult brain glial cells do 
not divide, unless a reactive proliferation is required [48]. Since there is no link between 
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events such as head trauma that could stimulate reactive proliferation of glial cells and the 
incidence of glioma development, the astrocytic origin of GBM is unlikely. Further research 
focused on identification of normal brain stem cells have led to isolation of neuroectodermal 
stem cells in the subventricular zone band in the human brain, multipotent cells that displayed 
astrocytic characteristics [49]. It is therefore more likely that those proliferative, migratory 
and undifferentiated cells can undergo transformation and give rise to malignant glioma [50]. 
Glial progenitor cells have been shown to be more permissive to oncogenic transformation 
than more mature astrocytic cells and upon expression of Ras and Akt oncogenes they gave 
rise to GBM-resembling tumors in mouse brain [51]. Moreover, neural progenitor cells 
express the CSC marker CD133, supporting the stem/progenitor cell origin of GBM [52].   
 Cancer stem cells, the dormant driving force of a tumor, resemble stem cells of a 
developing tissue, often re-expressing proteins restricted to embryonic tissues that are absent 
in mature cells.  One of the oncofetal proteins that is important for normal brain development, 
highly expressed by several malignancies, but present only at low level in a few adult tissues 
is insulin-like growth factor 2 mRNA binding protein (Imp2, IGF2BP2) that belongs to 
Imp/VICKZ protein family [53]. Studies on chicken and Xenopus paralogues of Imp2 have 
shown their implication in mRNA localization, translation and stability [54]. Human Imp1 
and Imp3 have been associated with poor outcome in various malignancies, including 
pancreatic adenocarcinoma, prostate carcinoma, thyroid carcinoma, breast cancer, colon 
carcinoma, melanoma and ovarian cancer [55]. However, no underlying molecular 
mechanism has been found. Recently several studies provided new insight into Imp2 biology, 
showing its implication in type 2 diabetes [54], smooth muscle cell adhesion and motility [56] 
and overexpression in different cancer types [55]. 
 Taking into account the expression patterns of Imp2 – its importance for normal brain 
development [57], silencing in adult brain and re-expression in malignancies has made it an 
interesting target for investigation. Therefore, we sought to determine Imp2 expression and 
functional relevance in GBM CSC. 
 During this investigation new observations concerning CSC metabolism were noted. 
Since cancer is a disease of abnormal proliferation, cancer cells have high energy demands to 
support their growth and survival. The primary way of energy production in any cell is to 
metabolize glucose to carbon dioxide via generation of pyruvate in glycolysis and its 
oxidation in mitochondrial tricarboxylic acid cycle (TCA)[58].  
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Figure 7. Glucose metabolism fuels ATP production; Pyruvate, produced during glycolysis can 
be transported to the mitochondria, where it fuels TCA cycle and NADH production; NADH 
oxidation is an electron source for the oxidative phosphorylation chain; the electron transport 
forces the extrusion of protons from the mitochondria, creating a transmembrane potential; this 
potential energy, the proton motive force, is then used for the ATP synthesis;  
 
 
 
The by-product of TCA, NADH is used as electron donor for the oxidative phosphorylation 
chain, where electrons are transferred via respiratory chain complex proteins I-IV to oxygen, 
proton gradient across the mitochondrial membrane is established and used to fuel ATP 
synthesis (Fig. 7). This chain of events allows for production of 36 moles of ATP per mole of 
glucose. However, this efficient synthesis of ATP requires constant glucose and oxygen 
supply. Since in a growing tumor increasing distance from the vascular capillaries can lead to 
local hypoxia and decrease in glucose availability, cancer cells have developed another 
strategy to support their rapid proliferation. In the process of anaerobic glycolysis, 
independent of oxygen supply, glucose is metabolized to pyruvate, which instead of being 
directed to the TCA cycle, is used for lactate production (Fig. 7). Although it seems wasteful, 
as most of the lactate is excreted from the cell, a by-product of this reaction is NADPH 
required for macromolecule synthesis. Therefore, although anaerobic glycolysis yields only 2-
4 moles of ATP per mole of glucose, it generates building material for macromolecules 
required for cellular proliferation. This process is also faster, enhancing the rapid growth of a 
tumor. Yet, it is not clear if all tumor cells switch to anaerobic glycolysis and, what is more 
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interesting, if cancer stem cells are also metabolically different from the bulk tumor 
counterparts. 
 
 
Results summary 
 
In order to determine the expression of Imp2 in glioblastoma an immunohistochemical 
staining of normal brain, low grade gliomas and 50 cases of GBM were compared (Fig. 8A). 
Imp2 is absent in normal brain and in low grade gliomas, but 75% GBM cases revealed 
moderate to high levels of Imp2 staining. The result was confirmed by bioinformatic analysis 
of Sun database [59], showing a correlation between glioma grade and Imp2 expression (Fig. 
8B). The expression of Imp2 was increased in GBM CSC, as shown by real-time Q-PCR in 
CD133+ cells compared to CD133- counterparts and by immunofluorescence in neurospheres 
compared to adherent, differentiated GBM cells. 
 To establish the importance of Imp2 expression in GBM CSC a shRNA was designed 
and delivered to the GBM primary cultured cells grown as neurospheres. Effective silencing 
of Imp2 has decreased GBM CSC sphere formation capacity and tumorigenesis (Fig. 8 C-D). 
Next, Imp2 immunoprecipitation was performed, to pull down Imp2-bound mRNA 
species and Imp-2 interacting proteins, that are present in ribonucleoprotein particles. Again, 
primary cultures of GBM CSC were used for the experiment. Microarray analysis of the 
transcripts, as well as mass-spectrometry of Imp2 interactors revealed that there is an 
overrepresentation of mitochondria related molecules. In the transcript analysis a significant 
proportion of mRNAs that are associated with mitochondrial functions were found. Protein 
interactor analysis revealed that Imp2 binds several subunits of respiratory complex I, all 
involved in early steps of complex I assembly. 
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Figure 8. Imp2 expression in GBM and its implication in GBM CSC self-renewal and tumorigenicity; A - 
immunohistochemical staining of paraffin sections shows lack of Imp2 expression in normal brain and low grade 
gliomas and a spectrum of positive staining in GBM ; B ––  Imp2 expression across gliomas of different grade in 
an independent data set (Sun et al) ; t-test P values : GBM vs normal: p=9.678e-11; GBM vs grade II/III 
oligodendroglioma: p =0.006351; GBM vs grade II/III astrocytoma: p =4.310e-05; C - Stable Imp2 shRNA 
expression impairs sphere formation in three batches of GBM CSC (BT-1, BT-2 and BT-3; * - P value 0.0227, 
** - P value 0.0015, ***- P value 0.0008, unpaired two-tailed t-test); error bars represent standard deviations; D 
– Imp2 shRNA expression diminishes GBM CSC tumor forming capacity; the experiment was repeated in three 
batches of cells (circles, squares and triangles); 6 animals were used per condition; since tumor formation by 
different BTs varied over time, a timescale of the experiment is presented (with the final time point as 100); the 
differences between Imp2 and ctrl shRNA expressing cells for each cell batch are significant (Log-rank (Mantel-
Cox) test P value for BT-1 is 0.0088, BT-2 is 0.0036, BT-3 is 0.0003); 
 
 
  The interactions of Imp2 with transcripts and proteins involved in oxidative 
phosphorylation chain pointed to its influence on the mitochondrial activity of GBM CSC. 
Knock-down of Imp2 impaired mitochondrial activity of those cells (Fig. 9), had an important 
effect on oxygen consumption and enzymatic activity of respiratory complex I.  
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Figure  9. Imp2 depletion affects oxidative respiration in GBM CSC; A – MitoTracker Red staining of active 
mitochondria decreases in cells depleted of Imp2; representative graphs of 3 experiments with different cell 
batches are shown; B – diminished oxygen consumption rate (OCR) is caused by Imp2 shRNA expression in two 
cell batches (BT-1 and BT-2); **** - P value < 0.0001 (paired two-tailed t-test); error bars represent standard 
deviation; C - Calcein AM staining was performed immediately after OCR measurement to ensure equal seeding 
of viable cells for the oxygen consumption measurement; D – 1µM rotenone injection decreases OCR of ctrl 
cells to a level comparable to that measured in Imp2 depleted cells; **** - P value < 0.0001, ns – not significant 
(two-way ANOVA with Bonferroni’s multiple comparison test); error bars represent standard deviation; E - cells 
depleted of Imp2 accumulate mitochondria; Q-PCR comparison of mitochondrial (16S) to nuclear (18S) DNA 
content; bars represent mean of two independent experiments on GBM CSC; error bars represent standard 
deviation; F – respiratory complex I activity is lowered by Imp2 knock-down, as shown by Blue Native PAGE 
and in-gel activity assay; 40µg or 100µg of the mitochondrial extracts were loaded on the gel; 
 
 Gliomas were thought to depend mainly on anaerobic glycolysis as an energy 
producing pathway [60]. Yet, inhibition of oxidative phosphorylation (OxPhos) had a sever 
effect on GBM CSC sphere morphology and clonogenic capacity, that resembled the 
phenotype of Imp2 knock-down cells (Fig. 10). Interestingly, inhibition of anaerobic 
glycolysis was not affecting the sphere formation. 
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Figure 10. Inhibition of oxidative phosphorylation impairs clonogenicity and survival of GBM CSC; silencing of 
Imp2 affects GBM CSC sphere morphology in the same way as inhibition of oxidative phosphorylation with 
1µM rotenone treatment (left panel); the clonogenic potential is diminished by Imp2 shRNA expression (Fig. 8) 
and by rotenone treatment (upper right panel; ** - P value 0.0024, unpaired two-tailed t-test); anaerobic 
glycolysis inhibition by 25mM oxamic acid does not significantly affect the clonogenic potential of GBM CSC; 
representative results for one out of three cell batches are shown; error bars represent the standard deviation; 
 
 
 The main findings of this work were: 
 Imp2 expression is restricted to GBM and is high in GBM CSC 
 Imp2 knock-down impairs GBM CSC self-renewal and tumorigenic capacity 
 Imp2 regulates OxPhos in GBM CSC 
 GBM CSC depend on OxPhos, whereas more differentiated cells depend on 
glycolysis 
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Discussion and perspectives 
 
Cancer cells develop an array of changes in their genetic, metabolic and histological 
properties, all of which are connected with increased cellular proliferation. It has been 
postulated that rapidly dividing cancer cells fulfill their enhanced energetic requirements by 
glycolysis. Even in the presence of oxygen, cancer cells use glucose to produce only small 
amounts of ATP, but high levels of lactate and biosynthetic intermediates used to increase the 
biomass of a tumor. These events, known as the Warburg effect, are often accompanied by 
mitochondrial gene mutations, which impair mitochondrial respiration.  However, an 
increasing number of studies reveal that oxidative phosphorylation is functional in many 
tumor types [60, 61]. This preference for OxPhos might be related to decreasing availability 
of glucose in a growing tumor and an increase of glutamine degradation, a way to fuel 
OxPhos. The results presented in this work also suggest another explanation for the OxPhos 
phenotype of some tumors. Since GBM cancer stem cells are highly dependent on OxPhos, it 
is plausible that overall oxidative potential of a tumor is maintained by high proportion of 
cancer stem cells and their progeny that still shares the metabolic properties.  
Non-transformed cells use OxPhos as the main energy supplying pathway, since it 
produces more ATP per mole of glucose, the oxygen and nutrient supply is constant. There 
are not many data about the bioenergetics of normal stem cells. However, there have been 
reports connecting metabolism and cell differentiation. Higher mitochondrial respiration has 
been shown to correlate with expression of the neural stem cell marker nestin in cultured 
neurospheres, suggesting that OxPhos is a hallmark of stem cells [62]. The importance of 
OxPhos in stem cells has also been confirmed by the observation of higher oxygen 
consumption rates in embryonic stem cells at early compared to late passages [63]. What is 
more, active mitochondrial metabolism was shown to discriminate mouse embryonic stem 
cell potential for teratoma formation [64]. OxPhos activity is also required for transformation 
of mesenchymal stem cells [65]. These data, together with observation gathered in this work, 
suggest that mitochondrial respiration can be another common feature shared by normal stem 
cells and cancer stem cells. The link between OxPhos and transformation of stem cells could 
also support the hypothesis that CSC are derived from normal stem cells. 
Active mitochondrial respiration requires efficient oxygen supply. The Warburg 
hypothesis suggests that cancer cells use anaerobic glycolysis, independent of oxygen 
availability. Yet, the results of this work imply that OxPhos is crucial for CSC survival, 
suggesting that they must also require oxygen. It has been shown by several groups that brain 
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CSC reside in close proximity to the blood vessels, in a perivascular niche [66-68]. It was also 
reported that GBM CSC can differentiate to endothelial cells, taking part in de novo vessel 
formation [68, 69]. Interestingly, access to the vasculature is also characteristic for neural 
stem cell niches [69]. These findings support the notion that normal stem cells and CSC share 
the oxygen dependence. 
 In the present work the role of Imp2 in GBM CSC was investigated. Experimental 
evidence show that Imp2 expression is crucial for normal respiratory chain function in GBM 
CSC and that Imp2 modulates OxPhos also when overexpressed in astrocytes, suggesting that 
this new function of IGF2 mRNA binding protein is not necessarily cell-specific. Genome 
wide association studies have shown an important single nucleotide polymorphism in Imp2 
gene in patients with type 2 diabetes [54]. This disease can be characterized by defects in 
insulin responsiveness in skeletal muscle and liver cells and aberrant insulin secretion by 
pancreatic β cells. Both of these features can be linked to mitochondrial dysfunction, observed 
as decreased expression of nuclear-encoded genes regulating mitochondrial functions and 
decreased OxPhos activity [70]. Following the conclusion of the present work, it is plausible 
that mutations of Imp2 are also interfering with its expression and function in skeletal muscles, 
liver and pancreas, distorting OxPhos and accounting significantly for the disease phenotype. 
 Imp2 interactions with OxPhos proteins and mitochondria-related transcripts do not 
explain the exact mechanism of metabolic control governed by this protein. There are two 
lines of research that could lead to further characterization of Imp2 function. First, Imp2 could 
serve as a mitochondrial delivery system. mRNAs bound by Imp2 are all encoded by nuclear 
genes, yet their protein counterparts are often found in mitochondria. It has been shown that 
translation of this kind of proteins can occur on the surface of mitochondria, on mitochondria-
associated polyribosomes [71]. Imp2 also can be found on the surface of mitochondria. 
Therefore, isolation of mitochondria-associated polysomes in the presence or absence of Imp2 
and quantification of Imp2-bound transcripts on those polysomes could provide results to 
support mitochondrial transporter function of Imp2. In this model interaction with respiratory 
complex I proteins could serve as a signal for Imp2 cargo release. However, the proteins of 
complex I that were bound by Imp2 are all implicated in the early steps of complex assembly. 
It is plausible that Imp2 serves as a docking molecule for the assembly seed or as a delivery 
system governing the assembly of complex I. Interestingly, since complex I is the electron 
entry point for the respiratory chain, its defects can severely affect the whole system, also by 
impairment of multicomplex assembly. Thus, it could be that Imp2 controls complex I 
assembly initiation, that provides a signal for further assembly of respiratory chain complexes. 
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 As shown in the above section, Imp2 is highly expressed in glioblastoma and GBM 
CSC and it is absent or less abundant in low grade gliomas and more importantly it is not 
expressed in normal brain samples. Only one study aimed at determining Imp2 expression in 
normal human tissues [72], showing that it is present in gonads. In mouse tissues the highest 
level of Imp2 expression was observed in the brain [73]. Yet, it is not clear whether Imp2 
expression is restricted to cancer cells and stem cells, as it is an oncofetal protein. However, at 
least in the brain, Imp2 seems to constitute an interesting therapeutical target. Since it is an 
mRNA binding protein, designing a sequence that could compete with its targets could be a 
potential approach towards a specific drug design for GBM patients. Further studies of Imp2 
role in other cancer and normal stem cell systems would be necessary to evaluate safety of 
such potential treatment. 
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Running title: Imp2 in glioblastoma cancer stem cells 
 
Abstract 
Cancer stem cells (CSC) occupy the apex of the cellular hierarchy in numerous cancer 
types, having the capacity for self-renewal and generation of non-tumourigenic progeny. 
These cells are believed to constitute the driving force of tumour development and 
progression but neither their energy requirements nor the mechanisms that regulate 
their energy production are known. Here, we show that the oncofetal insulin-like growth 
factor 2 mRNA binding protein 2 (IMP2, IGF2BP2) regulates oxidative phosphorylation 
(OXPHOS) in glioblastoma (GBM) CSC. We provide evidence that IMP2 binds several 
nuclear-derived mRNAs that encode mitochondrial respiratory chain complex proteins 
and that it interacts with Complex I (NADH:ubiquinone oxidoreductase) subunits. 
Depletion of IMP2 in GBM CSC causes a decrease in their oxygen consumption rate and 
in Complex I activity that results in decreased clonogenicity in vitro and tumourigenicity 
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in vivo. Importantly, inhibition of OXPHOS abolishes GBM CSC clonogenicity whereas  
inhibition of glycolysis has no effect. Our observations suggest that GBM CSC are 
dependent on OXPHOS but not on glycolysis for their energy production and survival 
and that IMP2 re-expression provides a key mechanism to ensure OXPHOS 
maintenance by addressing respiratory chain subunit encoding mRNA to mitochondria.      
 
 
Introduction 
A growing number of malignancies are recognized to be composed of phenotypically 
heterogeneous cells that are hierarchically organized and have diverse degrees of 
differentiating and proliferative capacity (Clevers, 2011). At the apex of the hierarchy are 
slowly cycling, undifferentiated cells that can self-renew, give rise to proliferating cell 
subpopulations and reconstitute a phenocopy of the primary tumour upon injection into 
immunocompromized mice – properties that have earned them the denomination of cancer 
stem cells (CSC). CSC can be functionally defined based on no more than a handful of 
properties, including their ability to form spheres in vitro under serum-free conditions, initiate 
tumour formation in vivo and display higher resistance to conventional anticancer therapy 
than their non-spherogenic counterparts (Dean et al., 2005). Yet, numerous key biological 
properties of these cells that may lead to a better understanding of their behaviour in addition 
to disclosing their potential therapeutic targetability need to be elucidated.  
Because CSC display plasticity that is typically associated with developing tissues, oncofetal 
proteins may participate in and potentially even determine many of their phenotypic and 
functional features. The oncofetal protein Imp2 is expressed in the developing mammalian 
brain and is required for normal embryonic development (Christiansen et al., 2009). Imp2 is 
an mRNA binding protein that plays an important role in subcellular mRNA localization, 
translation and stability (Christiansen et al., 2009). Studies on paralogue proteins IMP1 and 
IMP3 have shown a correlation between their expression and poor outcome in various 
malignancies, including pancreatic adenocarcinoma, prostate carcinoma, thyroid carcinoma, 
breast cancer, colon carcinoma, melanoma and ovarian cancer (Dimitriadis et al., 2007; 
Himoto et al., 2005; Kobel et al., 2007; Yaniv and Yisraeli, 2002), but mechanisms that 
underlie their functional implication in tumor biology have not been identified so far. Recent 
evidence suggests that Imp2 is implicated in type 2 diabetes (Christiansen et al., 2009) and in 
regulating smooth muscle cell adhesion and motility (Boudoukha et al., 2010) but with the 
exception of its expression in diverse malignancies (Hammer et al., 2005), virtually nothing is 
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known about its role in cancer. Because of its expression in the developing brain, we chose to 
address its possible functional role in glioblastoma (GBM) CSC. 
Glioblastomas (grade IV astrocytomas) are among the most malignant form of brain tumour 
with a survival time of approximately one year and  notorious resistance  to conventional anti-
cancer therapy(Louis, 2006). Cells that fulfil the currently accepted functional CSC criteria 
have been isolated from GBM based on their expression of diverse cell surface markers, 
including CD133 (Singh et al., 2004), SSEA1 (Son et al., 2009) and CD44 (Anido et al., 
2010). Glioblastoma thus provides a suitable solid tumor model to investigate CSC properties. 
We therefore addressed IMP2 expression, the repertoire of its target mRNAs and its 
functional relevance in GBM. 
 
Results and discussion 
Immunohistochemical staining of normal brain tissue and a panel of gliomas of varying 
grades revealed that Imp2 is absent in normal brain and grade II and III gliomas (Fig.1A), 
whereas 40 out of 51 GBM samples were Imp2-positive (data not shown). These observations 
were confirmed by microarray analysis of Imp2 expression in an independent dataset of 153 
gliomas of different grades and 23 normal samples (Sun et al., 2006) (Fig. 1B). Quantitative 
real-time PCR (Q-PCR) on extracts from primary GBM cells sorted for expression of the 
CSC-associated marker CD133 showed higher Imp2 expression in CD133+ than in CD133- 
GBM cells (Fig.1C, left). To investigate the role of Imp2 in GBM CSC in vitro, we used 
primary human GBM cells derived from three independent tumours (BT1-3) cultured as 
spheres in serum-free conditions. All three isolates have been shown to form tumours in vivo 
that are a phenocopy of the tumour they were derived from (Suvà et al., 2009). Consistent 
with our Q-PCR data, a high level of Imp2 expression was observed in gliospheres, as 
assessed by immunofluorescence (Fig.1C, right).  
To begin to address its putative role in GBM CSC, Imp2 ribonucleoprotein (RNP) complexes 
were immunoprecipitated and Imp2-bound mRNA transcripts were analyzed on Affymetrix 
microarrays. In parallel, pull-down experiments using anti-Imp2 antibody were performed to 
identify Imp2-bound proteins. Among 400 transcripts that were bound by Imp2, significant 
overrepresentation of genes implicated in mitochondrial function and OXPHOS was found 
(Fig. 2A and 2B, Supplemental Table 1). Implication of Imp2 in OXPHOS was supported by 
the identification of several subunits of Complex I of the mitochondrial respiratory chain in 
the pulldown material (Fig. 2C). Complex I catalyzes electron transfer from NADH to 
ubiquinone and constitutes the main entry point of electrons into the respiratory chain (Carroll 
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et al., 2006; Murray et al., 2003). Two subunits, NADH dehydrogenase (ubiquinone) iron-
sulphur protein 3 (NDUFS3) and iron sulphur protein 7 (NDUFS7) that form part of the 
peripheral arm of the complex (Fernandez-Vizarra et al., 2009), as well as NADH 
dehydrogenase (ubiquinone) 1 alpha complex assembly factor 3 (NDUF3) were identified in 
the Imp2 pulldown. Interaction between Imp2 and NDUFS3 was validated by 
immunoprecipitation and Western blot analysis (Fig. 2D). 
 
To assess the functional relevance of Imp2 expression in GBM CSC, stable repression of 
Imp2 transcripts using specific shRNA sequences was performed. Imp2 depletion resulted in a 
decrease in NDUFS3 protein (Fig. 3A) and Imp2-bound transcript (Fig. 3B) levels. Cells 
depleted of Imp2 had markedly impaired ability to form spheres in clonogenic assays in vitro 
(Fig. 3C) and their capability to form tumours in vivo was also compromised (Fig. 3D). 
Expression of Imp2 shRNA altered the morphology of the spheres (Fig. 5), due, at least in 
part, to increased cell death as assessed by propidium iodide staining (Supplemental Fig. 1A). 
Interestingly, the observed cell death was not apoptotic, as no increase in caspase 3 activation   
(Supplemental Fig. 1B) and no difference in Annexin V staining between Imp2-expressing 
and Imp2-depleted cells (data not shown) were observed. It had been shown previously that 
cells bearing mutations that impair the mitochondrial respiratory chain alter their response to 
pro-apoptotic stimuli (Kwong et al., 2007). Notably, cells devoid of mitochondrial DNA or 
bearing mutations resulting in a global loss of respiratory chain complexes were found to be 
resistant to staurosporin (STS)- and thapsigargin (TG)-induced apoptosis (Kwong et al., 2007). 
Similarly, and in contrast to control shRNA expressing cells, Imp2-depleted cells did not 
undergo apoptosis in response to STS or TG (Supplemental Fig. 1C) leading to the conclusion 
that Imp2 may play a role in sustaining OXPHOS in CSC. 
 
To explore this possibility, we investigated the effect of Imp2 depletion on mitochondrial 
activity. MitoTracker Red staining that provides an indication of mitochondrial activity was 
significantly decreased in Imp2-depleted cells (Fig. 4A). However, based on the observation 
that cell death was increased among Imp-2-deficient cell populations, decreased 
mitochondrial activity could simply reflect lower overall numbers of viable cells with active 
mitochondria. To address possible changes in mitochondrial activity following Imp2 depletion, 
oxygen consumption and extracellular acidification rate measurements were made in equal 
numbers of GBM CSC depleted or not of Imp2. Cells expressing Imp2 shRNA displayed a 
significantly decreased oxygen consumption rate (Fig. 4B), but an unaltered extracellular 
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acidification rate (data not shown). Because the assay was performed on live cells, equal 
viable cell seeding could be verified by Calcein AM staining (Fig. 4C) following the 
measurements. Inhibition of respiratory Complex I by addition of rotenone to the cell culture 
medium during the measurement decreased the oxygen consumption rate of control shRNA 
expressing cells to the level measured in Imp2 deficient cells (Fig. 4D), supporting the notion 
that the difference in oxygen consumption rate was due to a defect in OXPHOS. Next, we 
excluded impairment of mitochondrial biogenesis as an explanation for the oxygen 
consumption decrease.  Q-PCR  for mitochondrial DNA content showed that cells depleted of 
Imp2 had higher mitochondrial numbers (Fig. 4E), consistent with accumulation of 
functionally impaired mitochondria that is observed in several mitochondrial diseases and that 
may reflect a compensatory event (Johannsen and Ravussin, 2009).  
 
To further address the relationship between Imp2 and mitochondrial respiration, the effect of 
Imp2 introduction was assessed in astrocytes in which its expression is undetectable by 
immunocytochemistry and barely detected at the transcript level. Overexpression of Imp2 in 
the human astrocyte cell line SVGp12 resulted in increased Imp2 interacting protein levels, 
augmented mitochondrial function, as assessed by MitoTracker Red staining and a higher 
oxygen consumption rate (Supplemental Fig. 2). To determine whether the observed effects 
could be related to changes in Complex I activity, we performed a Blue Native PAGE (BN-
PAGE) that allowed us to separate mitochondrial respiratory chain complexes and to perform  
in-gel measurements of their enzymatic activity (Nijtmans et al., 2002). Mitochondrial 
extracts from GBM CSC stably transfected with Imp2 shRNA showed a marked decrease in 
complex I activity (Fig. 4F).  
 
The mechanism whereby Imp2 controls mitochondrial metabolism could involve stabilization 
of its target mRNAs and/or their subcellular localization to the vicinity of mitochondria. To 
determine whether degradation of Imp2 target mRNAs depends on its expression, cells 
overexpressing or depleted of Imp2 were treated with actinomycin D to block mRNA 
polymerization. Degradation of a panel of target transcripts was then assessed at several time 
points for a total of 12 hours (Supplemental Fig. 3A). Although the expression level of the 
target RNAs was dependent on that of Imp2, the slope of the decay curve was not altered, 
suggesting that Imp2 does not play a major role in its target mRNA stability. Next, Imp2 
localisation was assessed by Western blot analysis of subcellular GBM CSC fractions using 
anti-Imp2 antibody. Imp2 was found in the cytoplasm as well as in intact mitochondria, where 
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NDUFS3 is also located (Supplemental Fig. 3B, lane 2). Proteinase K treatment of 
mitochondria abolished Imp2 detection consistent with its localization on the mitochondrial 
surface (Supplemental Fig. 3B, lane 3). Partial degradation of NDUFS3 observed following 
proteinase K treatment suggests that a fraction of its cellular content is localized on the 
mitochondrial surface where interaction with Imp2 may occur. Together, these observations 
suggest at least two candidate mechanisms that may underlie Imp2-dependent OXPHOS 
regulation. First, Imp2 may serve to deliver nuclear transcripts that encode mitochondrial 
respiratory chain complex subunits to the mitochondrial surface where the corresponding 
protein synthesis occurs. Complex I subunits with which Imp2 interacts may serve as a 
mitochondrial surface docking platform for the corresponding ribonucleoprotein particles. 
Second, Imp2 interaction with Complex I subunits may influence their stability, assembly and 
possible formation of supercomplexes with Complex III and IV that appear to be necessary 
for respiratory activity (Fernandez-Vizarra et al., 2009)  
 
Our observations provide evidence that GBM CSC require an intact respiratory chain to 
sustain their tumourigenic potential. To address the relative importance of oxidative 
phosphorylation and anaerobic glycolysis in GBM CSC we used inhibitors of each pathway, 
including rotenone, which blocks Complex I activity, and oxamic acid, which abrogates 
lactate dehydrogenase (LDH), respectively. Rotenone treatment recapitulated the effect of 
Imp2 shRNA on GBM CSC with disruption of sphere morphology and abrogation of 
clonogenicity (Fig. 5). By contrast, oxamic acid increased the number of spheres in culture 
(although this effect was not significant) as shown by post-treatment clonogenic assays. The 
same assays were then performed on differentiated primary GBM cells obtained by culturing 
CSC in serum-containing medium, instead of “spherogenic” medium (Singh et al., 2004). 
Following treatment with rotenone, adherent GBM cells underwent transient attenuation of 
proliferation from which they rapidly recovered (Supplemental Fig. 4A). By contrast, viable 
cell counts after oxamic acid treatment revealed a 40% decrease in cell number in comparison 
to control cells (Supplemental Fig. 4B). Comparison of oxygen consumption rates between 
astrocytes, and CSC that were allowed to adhere to culture plates or maintained as spheres 
expressing or not Imp2 shRNA, revealed significant differences in metabolic activity 
(Supplemental Fig. 4C). Remarkably, CSC maintained as spheres that we have shown to rely 
heavily on mitochondrial respiration, had a far lower oxygen consumption rate than either 
primary astrocytes or adherent GBM cells. 
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Bioenergetic reprogramming constitutes part of the profound alterations induced by 
transformation and the ensuing changes in growth patterns and augmented anabolism impose 
increased energy requirements on transformed cells compared to their normal counterparts 
(Hanahan and Weinberg, 2011). The longstanding view, first proposed by Warburg, is that 
these requirements are primarily fulfilled by glycolysis even in the presence of adequate 
oxygen supply (Vander Heiden et al., 2009). Glycolysis provides rapid but inefficient energy 
production, generating 2-4 moles of ATP per mole of glucose. However, glucose along with 
glutamine is the major source of carbon, free energy and reducing equivalents required to 
support cell growth and division. Thus, a substantial portion of glucose is likely to be used to 
generate macromolecular precursors of fatty acid, non-essential amino acid and nucleotide 
synthesis in proliferating cells. Nevertheless, glycolysis is not a major energy source in all 
cancer cells (Jose et al., 2010) and those that have not sustained major mitochondrial damage 
or corresponding DNA mutations, may alternate between OXPHOS and glycolysis depending 
on their state and microenvironment. Slowly proliferating cells, such as CSC, may utilize the 
more efficient OXPHOS pathway that yields 36 moles of ATP per mole of glucose. Oxygen 
supply, required for OXPHOS, is probably more readily available for GBM CSC than for 
more differentiated GBM cells based on the observations that GBM CSC reside in the 
proximity of blood vessels (Calabrese et al., 2007) and that they may even generate tumour 
endothelium (Ricci-Vitiani et al., 2010; Wang et al., 2010). As CSC progeny proliferates, 
increased anabolic requirements and/or genetic mutations that inactivate mitochondria could 
force the cells to switch to a predominantly glycolytic metabolism. Hypoxic tumour regions 
with diminished nutrient supply may further select for survival of cancer cells that can 
efficiently switch to glycolysis (Rodriguez-Enriquez et al., 2010). It is therefore plausible that 
the hierarchical cellular organization within a tumour is also reflected in metabolic differences 
between cancer cells.  
 
Our study provides the novel observations that an mRNA binding oncofetal protein, Imp2, 
controls OXPHOS in GBM CSC and that OXPHOS is essential for CSC survival, 
clonogenicity and tumour initiating potential. In addition to providing new insight into 
mechanisms of energy production in GBM CSC, these findings may have important clinical 
implications as Imp2 is not expressed in normal brain and its inhibitors may provide an 
attractive therapeutic option in glioblastoma.  
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Materials and methods  
 
Chemical compounds and treatments 
For the apoptosis induction assay BT cells were treated with 1µM staurosporin (STS, kindly 
provided by Phil Shaw) or 1µM thapsigargin (TG, Tocris Bioscience) for 6h and 24h, 
respectively. Treatment duration was chosen to induce minimal apoptotic response. 
For mRNA degradation studies 10µg/ml actinomycin D (Sigma) was added to cell growth 
medium. RNA was collected after 0, 4, 8 and 12h of treatment. 
Inhibition of OXPHOS was achieved by 1µM rotenone (Sigma). Lactate dehydrogenase 
inhibitor oxamic acid was used at 25mM to block glycolysis. Both treatments were applied for 
72h. 
 
Tumor samples, CSC culture, adherent primary cultures and clonogenic assay 
Experimental procedures were performed as previously described (Suvà et al., 2009). 
 
Imp2 knockdown and retroviral infection 
The shRNA sequences targeting Imp2 were: sh1 – sense strand: 5’ 
GATCCACCAAACTAGCCGAAGAGATTCAAGAGATCTCTTCGGCTAGTTTGGTTTT
TTTACGCGTG3’, antisense strand: 5’AATTCACGCGTAAAAAAACCAAACTAGCCGA 
AGAGATCTCTTGAATCTCTTCGGCTAGTTTGGTG3’; sh2 – sense strand: 
5’GATCCGCGGAAAGAACCATCACTGTTTCAAGAGAACAGTGATGGTTCTTTCCGT
TTTTTACGCGTG3’, antisense strand: 5’AATTCACGCGTAAAAAACGGAAAGAACCA 
TCACTGTTCTCTTGAAACAGTGATGGTTCTTTCCGCG3’. Sense and antisense 
oligonucleotides were annealed to form duplexes and inserted into the pSIREN-Retro Q 
retroviral vector (BD Biosciences Clontech), according to the manufacturer's 
recommendations. Imp2 or control shRNA plasmids were transfected into GP2 packaging 
cells to produce the virus used to infect target gliomaspheres. Viral supernatant was 
concentrated by ultracentrifugation using a SW28 rotor (Beckman Coulter) at 19,500 rpm for 
90 min. Concentrated virus was added to dissociated spheres. Forty-eight hours later, cells 
were selected for puromycin (2 μg/ml) resistance for 5 days. The efficiency of the Imp2 
knockdown was verified by real-time quantitative PCR and Western blot analysis.  
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Imp2 overexpression 
The PCR product generated with following primers: Fwd 5’GAAGATCTTCCCAC 
CATGATGAACAAGCTTTACATC3’, Rev 5’CGGAATTCTCACTTGCTGCGCTGTGA 
GGCGACT3’ on GBM CSC genomic DNA was cloned into pMSCV_puro vector 
(Clonetech). Human astrocyte cell line SVGp12 was infected with pMSCV_Imp2 or empty 
vector containing virus according to the standard protocol. Cells were selected for puromycin 
(2 μg/ml) resistance for 7 days. 
Nonobese diabetic–severe combined immunodeficient mice xenotransplantation and 
survival analysis 
The in vivo experiments were conducted as described previously (Suvà et al., 2009). Six mice 
were used per condition. Survival analysis significance was calculated with log-rank test. 
Immunohistochemistry 
Paraffin-embedded sections of gliomas and normal brain were stained with mouse anti-human 
Imp2 (1:50 Dilution, Abcam). HRP staining was performed using biotin-conjugated rabbit 
anti-mouse IgG (Vector Laboratories) and revealed with a DAKO DAB Kit (DAKO).  
Immunofluorescence 
Gliospheres or adherent GBM cells were fixed with 4%PFA, washed, permeabilized with 3% 
Triton-X100, incubated with anti-Imp2 antibody (1:100, 0.5µg/ml, Abcam)  for 30min, 
followed by donkey anti-mouse-Alexa488 (1 :1300, Molecular Probes) and mounted in 
1 :1000 DAPI in mounting medium (ThermoShandon). Antibody specificity was compared to 
the isotype-matched control antibody. Images were acquired with Leica SP5 AOBS confocal 
microscope at the Imaging Core Facility of the University of Lausanne. The acquisition was 
performed in sequential mode to avoid dye crosstalk. 3D reconstruction of sphere staining 
was done with Imaris software. 
 
Q-PCR 
The procedure was performed as described previously (Suvà et al., 2009). For normalization, 
18S probe was used as the endogenous control. Q-PCR primers are presented in the table. 
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Gene name Fwd primer Rev primer 
Imp2 AACAGGACTGTCCGTGCTAT CTCTGGATAAGAGTGATGAT 
GPR160 CCAGCCATCTACCAAAGC ATCCTGATAGCCTGTACC 
POLR1D GAAGACCTCAATGGCTGAAG AGGATGGGTCGTAGTGTAAC 
TAF9B CCCTTTGCCACTGATTAAGC TTTGGGACAGACACCGTTTG 
Nxt2 AGGTAGTGACGCCGACACTG CCTGGTTAGTGCCCGTCTTC 
HMGA1 AAGGAGCCCAGCGAAGTGCCAAC AGCCTTGTCCAGGAGGGCATGTG 
DPH3 ATGACGAGGACTCGGAGAC GGGCTGGGACTGTTTCTCCACAC 
NDUFAF4 TCCTGCGAGAGCAGATTAGTC CGGCAATCTGAATTCCTTCGG 
COX7b GAAGCGAATTGGCACCAAAG GTGGCTCCACTAGCTAATAC 
COX7c GTGCCGCCATTTCATCTGTC AGGGTGTAGCAAATGCAGATCC 
COX16 GAACAAGACTCTCGGCTATGG TTGGAGGAGGTCAGGATCTTC 
CYB5b AAACCTGCCTCAGTAGAGTC CAGGCTCAAACGATAGGTTC 
MRLQ TCTCTTGCGTCTGGCATTG ATTGTGCGGATGTGGCTTC 
 
To determine mitochondrial content, Q-PCR was performed on DNA extracts using 18S 
primers (Fwd 5’ TAGAGGGACAAGTGGCGTTC3’, Rev 5’ CGCTGAGCCAGTCAGTGT 
3’) for nuclear DNA and 16S primers ( Fwd 5’ CACCCAAGAACAGGGTTTGT3’, Rev 5’ 
TGGCCATGGGTATGTTGTTAA3’) for mitochondrial DNA and the ratio of the two was 
calculated. 
 
Western blot 
Western blotting was performed according to standard procedures. The following antibodies 
were used: anti-Imp2 (0.5µg/ml, Abcam), anti-NDUFS3 (0.5µg/ml, Abcam), anti-PARP 
(0.5µg/ml, Cell Signalling), anti-caspase 3 p20 (0.2µg/ml, Santa Cruz), anti-β-actin 
(1.65µg/ml, Sigma), anti-α-tubulin (0.025µg/ml, Calbiochem). Secondary antibodies were 
horseradish peroxidase (HRP)–conjugated goat anti-mouse (GE Healthcare), mouse anti-
rabbit (DAKO) and rabbit anti-goat (DAKO) antibodies. 
 
Propidium iodide staining and cell cycle analysis 
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Cells were resuspended in 10ng/ml propidium iodide with 1% IGEPAL, vortexed, incubated 
overnight at 4°C and analyzed by FACS.  
 
Intact mitochondria isolation and proteinase K treatment 
Intact mitochondria were isolated from 20 x 10
6
 GBM CSC with Mitochondria Isolation Kit 
for Cultured Cells (Pierce). To remove proteins from the mitochondrial surface,  
mitochondrial pellets were resuspended in buffer C (Mitochondria Isolation Kit for Cultured 
Cells, Pierce) and treated with 50µg/ml proteinase K (Sigma) for 30min on ice and spun down 
at 10000xg for 10min. 
RIP-CHIP assay 
30 x 10
6
 BT cells were used per experiment. Imp2-bound RNA immunoprecipitation was 
performed according to the RiboCluster Profiler RIP-Assay Kit protocole (MBL Ribonomics). 
Eluted RNA was anaylzed at the DNA Array Facility Lausanne using Affymetrics Arrays. 
RIP-CHIP results generated from 3 different primary cultures were compared. Probe sets 
showing a false discovery rate < 0.05 and logarithmic fold changes > 2 in all three samples 
were subjected to further analysis. Gene Onthology annotations obtained for those probes 
were considered as overrepresented when the P value of exact one-tailed Fisher test was < 
0.00005.  
Pull-down assay 
80 x 10
6
 cells were collected in PBS with protein inhibitors, centrifuged, resuspended in 5 
volumes of the RIP-Assay lysis buffer (without addition of DTT) and sonicated for 10s. The 
lysate was centrifuged at 3500rpm for 5min at 4 C. Agarose protein-A beads (GE Healthcare), 
previously washed with wash buffer from the RIP-Assay kit, without DTT, were added to the 
supernatants and discarded after 2h of pre-clearing. Incubation with 20µg of anti-Imp2 or 
isotype matched control antibody was performed overnight at 4 C, and incubation with the 
beads for 4h. The beads were then washed 4 times with wash buffer. Mass-spectrometry 
analysis was performed at the Protein Analysis Facility of Faculty of Biology and Medecine, 
University of Lausanne. 
Mitotracker assay 
Cells were washed twice with PBS, resuspended in pre-warmed medium containing 250nM 
MitoTracker Red CM-H2XRos (Molecular Probes) or DMSO and incubated for 30min at 
37°C. After two washes with PBS, cells were resuspended in PBS and analyzed by FACS. 
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OCR/ECAR measurement 
20,000 to 50,000 cells per well were seeded in XF24 cell culture microplates (Seahorse 
Bioscience). For each cell type 5 replicates were made. Measurements for spherogenic cells 
were made immediately after sphere disruption and viable cell counting (Trypan blue 
exclusion) and following the assay, cell viability was verified (Calcein AM staining  (1:200, 
2mg/ml, Calbiochem) analyzed by FACS). For adherent cells, measurements were made 12-
16h after seeding, and absence of difference in cell proliferation was verified using a Cell 
Proliferation ELISA BrdU colorimetric assay (Roche).  
Blue Native PAGE and in-gel activity assay 
The mitochondrial extracts preparation, Blue Native gel electrophoresis and in-gel activity for 
respiratory complex I were performed as described (Nijtmans et al., 2002). 
Statistical methods  
Microarray gene expression data for non-malignant brain and different gliomas were obtained 
from Sun et al (Sun et al., 2006) (GEO accession GSE4290). Data were normalized with 
RMA and probes corresponding to the same gene were collapsed to the maximum value using 
the GenePattern software package (Reich et al., 2006). T-test p-values for sample 
comparisons were calculated using the R statistical software package (Team, 2010). 
P values were calculated with Graph Pad Prism 5 software, using statistical tests indicated in 
figure legends.  
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Figure legends 
Figure 1. Imp2 expression in GBM ; A - immunohistochemical staining of paraffin sections 
shows lack of Imp2 expression in normal brain and low grade gliomas and a spectrum of 
positive staining in GBM ; B ––  Imp2 expression across gliomas of different grade in an 
independent data set (Sun et al) ; t-test P values : GBM vs normal: p=9.678e-11; GBM vs 
grade II/III oligodendroglioma: p =0.006351; GBM vs grade II/III astrocytoma: p =4.310e-05; 
C – Imp2 expression is high in GBM CSC; Q-PCR for Imp2 in GBM CD133+ CSC (left 
panel, results for two independent cell batches are shown); immunofluorescence staining of 
CSC spheroid (3D reconstruction, middle panel) compared to differentiated cancer cells 
shows high Imp2 expression levels in cancer stem cells (right panel) ; green 
immunofluorescence: Imp2 staining, white: Imp2 channel 3D reconstruction (signal above 
threshold), blue: DAPI; two independent staining were performed; 
Figure 2. mRNA and proteins bound by Imp2 suggest a functional role in mitochondrial 
processes; A – specificity of RIP assay is presented by the heat map comparing transcripts 
obtained with anti-Imp2 and isotype matched ctrl antibody immunoprecipitation; results for 
three batches of primary GBM cultures in spherogenic conditions are shown; B - gene 
ontology analysis of Imp2-bound RNA shows overrepresentation of mitochondrial processes;  
GO term was considered enriched if the nominal P of the exact one-tailed Fisher test was less 
than 10
-5
; the length of the bar for each term is proportional to the number of bound mRNAs 
annotated to the term; the shaded part of the bar represents the number of annotated mRNAs 
expected by chance; C – mass-spectrometry analysis of Imp2-bound proteins suggests an 
interaction with mitochondrial respiratory complex I proteins ; D - immunoperecipitation of 
Imp2 (left panel) followed by Western blotting using an anti-NDUFS3 antibody and 
immunoprecipitation of NDUFS3 (right panel) followed by Western blotting using an anti-
Imp2 antibody confirm the interaction between the two proteins; 
Figure 3. Effects of Imp2 knock-down; A – Imp2 was efficiently silenced in GBM CSC stably 
expressing two different shRNAs; Imp2 depletion also decreased NDUFS3 protein levels; B – 
Imp2 knock-down decreases mRNA levels of Imp-2 bound transcripts; Q-PCR for two 
batches of GBM CSC (black and white bars) are shown; C – Stable Imp2 shRNA expression 
impairs sphere formation in three batches of GBM CSC (BT-1, BT-2 and BT-3; * - P value 
0.0227, ** - P value 0.0015, ***- P value 0.0008, unpaired two-tailed t-test); error bars 
represent standard deviations; D – Imp2 shRNA expression diminishes GBM CSC tumor 
forming capacity; the experiment was repeated in three independent batches of cells (circles, 
squares and triangles); 6 animals were used per condition; since tumor formation by different 
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BTs varied over time, a timescale of the experiment is presented (with the final time point as 
100); the differences between Imp2 and ctrl shRNA expressing cells for each cell batch are 
significant (Log-rank (Mantel-Cox) test P value for BT-1 is 0.0088, BT-2 is 0.0036, BT-3 is 
0.0003); 
Figure 4. Imp2 depletion affects oxidative respiration in GBM CSC; A – MitoTracker Red 
staining of active mitochondria decreases in cells depleted of Imp2; representative graphs of 3 
experiments with independent cell batches are shown; B – diminished oxygen consumption 
rate (OCR) is caused by Imp2 shRNA expression in two cell batches (BT-1 and BT-2); **** - 
P value < 0.0001 (paired two-tailed t-test); error bars represent standard deviation; C - Calcein 
AM staining was performed immediately after OCR measurement to ensure equal seeding of 
viable cells for the oxygen consumption measurement; D – 1µM rotenone injection decreases 
OCR of ctrl cells to a level comparable to that measured in Imp2 depleted cells; **** - P 
value < 0.0001, ns – not significant (two-way ANOVA with Bonferroni’s multiple 
comparison test); error bars represent standard deviation; representative of two experiments; E 
- cells depleted of Imp2 accumulate mitochondria; Q-PCR comparison of mitochondrial (16S) 
to nuclear (18S) DNA content; bars represent mean of two independent experiments on GBM 
CSC; error bars represent standard deviation; representative of two experiments; F – 
respiratory complex I activity is lowered by Imp2 knock-down, as shown by Blue Native 
PAGE and in-gel activity assay; 40µg or 100µg of the mitochondrial extracts were loaded on 
the gel; representative of three experiments; 
Figure 5. Inhibition of oxidative phosphorylation impairs clonogenicity and survival of GBM 
CSC; silencing of Imp2 affects GBM CSC sphere morphology in the same way as inhibition 
of oxidative phosphorylation with 1µM rotenone treatment (left panel); the clonogenic 
potential is diminished by Imp2 shRNA expression (Fig. 2) and by rotenone treatment (upper 
right panel; ** - P value 0.0024, unpaired two-tailed t-test); anaerobic glycolysis inhibition by 
25mM oxamic acid does not significantly affect the clonogenic potential of GBM CSC; 
representative results for one out of three independent cell batches are shown; error bars 
represent the standard deviation; 
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Supplemental material 
Supplemental Figure 1. Imp2 knock-down induces non-apoptotic cell death; A – cell cycle 
analysis (propidium iodide incorporation analyzed by FACS) shows a decrease in actively 
cycling cells and an increase in the amount of dead cells in the Imp2 shRNA expressing 
population; representative of two experiments; B – Imp2 knock-down does not induce 
apoptosis as caspase 3 cleavage is not enhanced by Western blot analysis; representative of 
two experiments; C – Imp2 depleted cells are resistant to inducers of apoptosis: apoptosis 
induction by treatment with 1µM staurosporin (STS) or 1µM thapsigargin (TG) for 6h or 24h, 
respectively; Western blots using anti-PARP and anti-caspase 3 p20 show weak induction of 
apoptosis in cells expressing ctrl shRNA but no effect of the drugs on Imp2 depleted cells; 
representative of two experiments; 
Supplemental Figure 2. Imp2 overexpression in human astrocytes; A – Western blot 
analysis of extracts from the SVGp12 human astrocyte cell line expressing pMSCV_Imp2 or 
ctrl (empty) vector; representative of two experiments; B – MitoTracker Red staining of 
active mitochondria is increased in SVGp12 cells overexpressing Imp2; representative of 
three experiments;C – overexpression of Imp2 increases oxygen consumption rate; *** - P 
value 0.0002 (paired two-tailed t-test); error bars represent standard deviation; the effect of 
cell proliferation on the OCR was excluded by BrdU incorporation assay (data not shown); 
representative of three experiments; 
Supplemental Figure 3. Imp2 could provide mRNA delivery system for mitochondria; A – 
degradation of Imp2-bound transcripts was measured after 0, 4, 8 and 12h after actinomycin 
D addition by Q-PCR; the lines represent linear regression; the slopes of the linear regression 
are not significantly different between Imp2 expressing and depleted cells; representative of 
15 transcripts tested; B – Imp2 localizes at the surface of mitochondria; subcellular 
fractionation: CYT – cytosolic fraction, MT – isolated mitochondria; Western blot for Imp2 
and NDUFS3 shows disappearance of Imp2 band upon proteinase K treatment of the intact 
mitochondria; representative of two experiments; 
Supplemental Figure 4. GBM CSC after differentiation in serum are less sensitive to 
inhibition of oxidative phosphorylation but more sensitive to glycolysis blockade;  A – GBM 
CSC cultured in medium containing serum acquire an adherent phenotype and are less 
sensitive to rotenone treatment than their spherogenic counterparts; left – adherent BT cells 
treated with DMSO; right - adherent BT cells treated with rotenone; B – the effect of oxamic 
acid (OXA) treatment on spherogenic (BT) and adherent BT (BTadh) cell numbers;  viable 
cell count was determined by trypan blue exclusion; * - P value is 0.0294 (one-way ANOVA, 
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Bonferroni`s multiple comparisons test for BTadh ctrl and OXA); error bars represent 
standard deviation; representative of two experiments; C - oxygen consumption rates in CSC 
compared with adherent BT and astrocytes; OCR in GBM CSC (BT) is significantly lower 
than in differentiated CSC (BT adh) and astrocytes; measurements were made for 50000 
cells/well, and each data point represents an independent experiment (mean for 5 wells). The 
horizontal line represents the mean of 3 experiments and the error bar corresponds to SEM; ns 
– not significant, ***- P<0.0005 (one-way ANOVA with Bonferroni`s multiple comparisons 
test), * - P value is 0.0161 (two-tailed paired t-test for comparison of BT (with ctrl shRNA) 
and BT with Imp2 shRNA); 
Supplemental Table 1. mRNAs bound by Imp2 in GBM CSC; List of microarray analysis of 
mRNA immunoprecipitated with anti-Imp2 antibody; only probesets that have rank-products 
false discovery rate FDR < 0.05 and fold change |M| > 2 included; 
 
 
 
  
62 
 
 
  
63 
 
 
64 
 
 
 
 
 
65 
 
 
 
 
 
 
 
 
 
  
66 
 
67 
 
probeset gene_id gene_symbol gene_name 
fold 
change pfp 
223423_at 26996 GPR160 G protein-coupled receptor 160 4.0806 0 
217645_at 51241 COX16 COX16 cytochrome c oxidase assembly homolog (S. cerevisiae) 3.8252 0 
206074_s_at 3159 HMGA1 high mobility group AT-hook 1 3.8807 0 
224874_at 51082 POLR1D polymerase (RNA) I polypeptide D, 16kDa 3.5445 0 
210457_x_at 3159 HMGA1 high mobility group AT-hook 1 3.5982 0 
224964_s_at 54331 GNG2 guanine nucleotide binding protein (G protein), gamma 2 3.4995 0 
209628_at 55916 NXT2 nuclear transport factor 2-like export factor 2 3.4149 0 
209362_at 9412 MED21 mediator complex subunit 21 3.4134 0 
227722_at 6228 RPS23 ribosomal protein S23 3.4569 0 
1553214_a_at 221016 CCDC7 coiled-coil domain containing 7 3.2871 0 
1569183_a_at 1121 CHM choroideremia (Rab escort protein 1) 3.3016 0 
224819_at 90843 TCEAL8 transcription elongation factor A (SII)-like 8 3.2376 0 
233543_s_at 84142 FAM175A family with sequence similarity 175, member A 3.2081 0 
201312_s_at 6451 SH3BGRL SH3 domain binding glutamic acid-rich protein like 3.2239 0 
209629_s_at 55916 NXT2 nuclear transport factor 2-like export factor 2 3.1827 0 
224740_at 643155 C5orf43 chromosome 5 open reading frame 43 3.0879 6.00E-04 
1566303_s_at 6992 PPP1R11 protein phosphatase 1, regulatory (inhibitor) subunit 11 3.0895 6.00E-04 
1564381_s_at - - - 3.0526 6.00E-04 
225195_at 285381 DPH3 DPH3, KTI11 homolog (S. cerevisiae) 2.983 5.00E-04 
232990_at 90736 FAM104B family with sequence similarity 104, member B 2.9878 5.00E-04 
220103_s_at 51023 MRPS18C mitochondrial ribosomal protein S18C 2.9853 5.00E-04 
201500_s_at 6992 PPP1R11 protein phosphatase 1, regulatory (inhibitor) subunit 11 2.9472 5.00E-04 
214183_s_at 8277 TKTL1 transketolase-like 1 2.9712 4.00E-04 
227158_at 112487 C14orf126 chromosome 14 open reading frame 126 2.972 4.00E-04 
225599_s_at 286144 C8orf83 chromosome 8 open reading frame 83 2.9058 4.00E-04 
225469_at 144363 LYRM5 LYR motif containing 5 2.9068 4.00E-04 
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235117_at 494143 CHAC2 ChaC, cation transport regulator homolog 2 (E. coli) 2.8999 4.00E-04 
212097_at 857 CAV1 caveolin 1, caveolae protein, 22kDa 2.8756 4.00E-04 
226556_at - - - 2.8904 3.00E-04 
231990_at 9958 USP15 ubiquitin specific peptidase 15 2.9044 3.00E-04 
235004_at 221662 RBM24 RNA binding motif protein 24 2.8747 3.00E-04 
227935_s_at 84333 PCGF5 polycomb group ring finger 5 2.8294 3.00E-04 
1557961_s_at 1E+08 LOC100127983 hypothetical protein LOC100127983 2.855 3.00E-04 
203323_at 858 CAV2 caveolin 2 2.8407 3.00E-04 
212532_s_at 124801 LSM12 LSM12 homolog (S. cerevisiae) 2.8577 3.00E-04 
224158_s_at 286144 C8orf83 chromosome 8 open reading frame 83 2.8062 3.00E-04 
219895_at 55026 FAM70A family with sequence similarity 70, member A 2.8224 3.00E-04 
217267_s_at 7879 RAB7A RAB7A, member RAS oncogene family 2.8039 3.00E-04 
235759_at - - - 2.7859 3.00E-04 
226037_s_at 51616 TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa 2.7717 2.00E-04 
218981_at 57001 ACN9 ACN9 homolog (S. cerevisiae) 2.7566 2.00E-04 
221616_s_at 51616 TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa 2.7366 2.00E-04 
201427_s_at 6414 SEPP1 selenoprotein P, plasma, 1 2.7662 2.00E-04 
212957_s_at 92249 LOC92249 hypothetical LOC92249 2.7378 2.00E-04 
201311_s_at 6451 SH3BGRL SH3 domain binding glutamic acid-rich protein like 2.7182 2.00E-04 
200703_at 8655 DYNLL1 dynein, light chain, LC8-type 1 2.7417 2.00E-04 
223037_at 51248 PDZD11 PDZ domain containing 11 2.7212 2.00E-04 
226521_s_at 84142 FAM175A family with sequence similarity 175, member A 2.725 2.00E-04 
229778_at 80763 C12orf39 chromosome 12 open reading frame 39 2.6247 2.00E-04 
201344_at 7322 UBE2D2 ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 2.7037 4.00E-04 
231819_at - - - 2.7097 4.00E-04 
218316_at 26520 TIMM9 translocase of inner mitochondrial membrane 9 homolog (yeast) 2.699 4.00E-04 
212440_at 11017 SNRNP27 small nuclear ribonucleoprotein 27kDa (U4/U6.U5) 2.721 4.00E-04 
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219926_at 64208 POPDC3 popeye domain containing 3 2.7062 4.00E-04 
225976_at 91408 BTF3L4 basic transcription factor 3-like 4 2.6843 4.00E-04 
1555766_a_at 54331 GNG2 guanine nucleotide binding protein (G protein), gamma 2 2.6675 5.00E-04 
201310_s_at 9315 C5orf13 chromosome 5 open reading frame 13 2.6712 5.00E-04 
226010_at 79085 SLC25A23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 2.66 5.00E-04 
227669_at 25874 BRP44 brain protein 44 2.6661 5.00E-04 
1553801_a_at 112487 C14orf126 chromosome 14 open reading frame 126 2.6879 5.00E-04 
225684_at 348235 SKA2 spindle and kinetochore associated complex subunit 2 2.6746 5.00E-04 
225600_at 286144 C8orf83 chromosome 8 open reading frame 83 2.6703 5.00E-04 
1553321_a_at 27233 SULT1C4 sulfotransferase family, cytosolic, 1C, member 4 2.6574 5.00E-04 
1558586_at 7582 ZNF33B zinc finger protein 33B 2.6631 5.00E-04 
222447_at 51108 METTL9 methyltransferase like 9 2.661 5.00E-04 
226775_at 56943 ENY2 enhancer of yellow 2 homolog (Drosophila) 2.6626 5.00E-04 
224965_at 54331 GNG2 guanine nucleotide binding protein (G protein), gamma 2 2.6534 4.00E-04 
211597_s_at 84525 HOPX HOP homeobox 2.6151 4.00E-04 
224767_at 6167 RPL37 ribosomal protein L37 2.6473 4.00E-04 
219596_at 56906 THAP10 THAP domain containing 10 2.6139 4.00E-04 
243444_at - - - 2.6406 4.00E-04 
208656_s_at 10983 CCNI cyclin I 2.6564 6.00E-04 
226776_at 56943 ENY2 enhancer of yellow 2 homolog (Drosophila) 2.6444 5.00E-04 
228483_s_at 51616 TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa 2.6139 5.00E-04 
224587_at 10923 SUB1 SUB1 homolog (S. cerevisiae) 2.6355 5.00E-04 
227299_at 10983 CCNI cyclin I 2.614 5.00E-04 
202678_at 2958 GTF2A2 general transcription factor IIA, 2, 12kDa 2.6234 5.00E-04 
217551_at 441453 LOC441453 similar to olfactory receptor, family 7, subfamily A, member 17 2.611 5.00E-04 
1570243_at 440731 - - 2.6202 5.00E-04 
1554167_a_at 51125 GOLGA7 golgi autoantigen, golgin subfamily a, 7 2.611 5.00E-04 
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239988_at - - - 2.5906 5.00E-04 
223784_at 57393 TMEM27 transmembrane protein 27 2.5672 5.00E-04 
230433_at 729970 LOC729970 similar to hCG2028352 2.5634 5.00E-04 
242317_at 25994 HIGD1A HIG1 hypoxia inducible domain family, member 1A 2.5845 5.00E-04 
1553133_at 203228 C9orf72 chromosome 9 open reading frame 72 2.6042 5.00E-04 
201745_at 5756 TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 2.6102 5.00E-04 
225053_at 29883 CNOT7 CCR4-NOT transcription complex, subunit 7 2.5883 5.00E-04 
1555906_s_at 285343 C3orf23 chromosome 3 open reading frame 23 2.5883 5.00E-04 
225603_s_at 286144 C8orf83 chromosome 8 open reading frame 83 2.6039 4.00E-04 
1555905_a_at 285343 C3orf23 chromosome 3 open reading frame 23 2.581 4.00E-04 
240711_at - - - 2.5945 4.00E-04 
225028_at 550643 LOC550643 hypothetical LOC550643 2.5738 4.00E-04 
218930_s_at 54664 TMEM106B transmembrane protein 106B 2.5928 4.00E-04 
230560_at 29091 STXBP6 syntaxin binding protein 6 (amisyn) 2.5473 4.00E-04 
241959_at 10393 ANAPC10 anaphase promoting complex subunit 10 2.5625 4.00E-04 
226338_at 55529 TMEM55A transmembrane protein 55A 2.5589 4.00E-04 
243998_at 125113 KRT222 keratin 222 2.5454 4.00E-04 
205569_at 27074 LAMP3 lysosomal-associated membrane protein 3 2.535 4.00E-04 
228107_at 1E+08 LOC100127983 hypothetical protein LOC100127983 2.569 6.00E-04 
222487_s_at 51065 RPS27L ribosomal protein S27-like 2.5425 6.00E-04 
202543_s_at 2764 GMFB glia maturation factor, beta 2.5476 6.00E-04 
240712_s_at - - - 2.5402 6.00E-04 
217988_at 57820 CCNB1IP1 cyclin B1 interacting protein 1 2.5448 6.00E-04 
230174_at 127018 LYPLAL1 lysophospholipase-like 1 2.5103 6.00E-04 
218946_at 27247 NFU1 NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae) 2.5267 7.00E-04 
222948_s_at 51023 MRPS18C mitochondrial ribosomal protein S18C 2.4951 7.00E-04 
225580_at 54534 MRPL50 mitochondrial ribosomal protein L50 2.5483 7.00E-04 
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202544_at 2764 GMFB glia maturation factor, beta 2.538 6.00E-04 
241017_at 11138 TBC1D8 TBC1 domain family, member 8 (with GRAM domain) 2.4543 6.00E-04 
235429_at - - - 2.4963 6.00E-04 
218139_s_at 55745 MUDENG MU-2/AP1M2 domain containing, death-inducing 2.4558 6.00E-04 
221726_at 6146 RPL22 ribosomal protein L22 2.5196 6.00E-04 
218007_s_at 51065 RPS27L ribosomal protein S27-like 2.5001 6.00E-04 
212595_s_at 9802 DAZAP2 DAZ associated protein 2 2.5096 6.00E-04 
223266_at 55437 STRADB STE20-related kinase adaptor beta 2.5086 6.00E-04 
241652_x_at - - - 2.5042 6.00E-04 
201691_s_at 7163 TPD52 tumor protein D52 2.4875 6.00E-04 
226596_x_at 729852 tcag7.903 hypothetical protein LOC729852 2.4883 6.00E-04 
225105_at 387882 C12orf75 chromosome 12 open reading frame 75 2.4994 7.00E-04 
217816_s_at 57092 PCNP PEST proteolytic signal containing nuclear protein 2.5058 8.00E-04 
203324_s_at 858 CAV2 caveolin 2 2.4735 7.00E-04 
229793_at 653308 ASAH2B N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2B 2.4755 7.00E-04 
235696_at - - - 2.4689 8.00E-04 
229146_at 136895 C7orf31 chromosome 7 open reading frame 31 2.4216 8.00E-04 
207276_at 1038 CDR1 cerebellar degeneration-related protein 1, 34kDa 2.4725 8.00E-04 
240027_at 8825 LIN7A lin-7 homolog A (C. elegans) 2.4693 8.00E-04 
209139_s_at 8575 PRKRA protein kinase, interferon-inducible double stranded RNA dependent activator 2.4234 9.00E-04 
214033_at 368 ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 2.423 9.00E-04 
201708_s_at 8508 NIPSNAP1 nipsnap homolog 1 (C. elegans) 2.427 9.00E-04 
203303_at 6990 DYNLT3 dynein, light chain, Tctex-type 3 2.435 9.00E-04 
223071_at 51124 IER3IP1 immediate early response 3 interacting protein 1 2.4648 9.00E-04 
239252_at - - - 2.3586 0.001 
206238_s_at 10138 YAF2 YY1 associated factor 2 2.423 0.0011 
200706_s_at 9516 LITAF lipopolysaccharide-induced TNF factor 2.4156 0.001 
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221727_at 10923 SUB1 SUB1 homolog (S. cerevisiae) 2.438 0.001 
224584_at 29058 C20orf30 chromosome 20 open reading frame 30 2.4271 0.001 
235354_s_at 51319 RSRC1 arginine/serine-rich coiled-coil 1 2.4334 0.001 
226633_at 51762 RAB8B RAB8B, member RAS oncogene family 2.3594 0.001 
242905_at 56902 PNO1 partner of NOB1 homolog (S. cerevisiae) 2.4279 0.001 
231640_at - - - 2.4199 0.001 
1559005_s_at 54875 CNTLN centlein, centrosomal protein 2.4289 0.0011 
1568951_at 54816 ZNF280D zinc finger protein 280D 2.3804 0.0011 
214658_at 51014 TMED7 transmembrane emp24 protein transport domain containing 7 2.3983 0.0011 
222750_s_at 79644 SRD5A3 steroid 5 alpha-reductase 3 2.4004 0.0011 
223667_at 51661 FKBP7 FK506 binding protein 7 2.4291 0.0011 
203622_s_at 56902 PNO1 partner of NOB1 homolog (S. cerevisiae) 2.3911 0.0012 
204017_at 11015 KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 2.3695 0.0012 
225413_at 84833 USMG5 up-regulated during skeletal muscle growth 5 homolog (mouse) 2.3902 0.0011 
223087_at 55862 ECHDC1 enoyl Coenzyme A hydratase domain containing 1 2.3919 0.0013 
225029_at 550643 LOC550643 hypothetical LOC550643 2.3666 0.0014 
225399_at 116461 TSEN15 tRNA splicing endonuclease 15 homolog (S. cerevisiae) 2.3487 0.0014 
204795_at 80742 PRR3 proline rich 3 2.3373 0.0014 
203007_x_at 10434 LYPLA1 lysophospholipase I 2.3438 0.0014 
225926_at 10490 VTI1B vesicle transport through interaction with t-SNAREs homolog 1B (yeast) 2.3095 0.0017 
201002_s_at 7335 UBE2V1 ubiquitin-conjugating enzyme E2 variant 1 2.3941 0.0017 
243887_at - - - 2.3579 0.0017 
225692_at 23261 CAMTA1 calmodulin binding transcription activator 1 2.3984 0.0018 
221620_s_at 79135 APOO apolipoprotein O 2.3628 0.0018 
209363_s_at 9412 MED21 mediator complex subunit 21 2.3665 0.0018 
230570_at - - - 2.3365 0.0018 
209714_s_at 1033 CDKN3 cyclin-dependent kinase inhibitor 3 2.3616 0.0018 
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219318_x_at 51003 MED31 mediator complex subunit 31 2.3694 0.0018 
229174_at 285237 C3orf38 chromosome 3 open reading frame 38 2.3253 0.0018 
218545_at 55297 CCDC91 coiled-coil domain containing 91 2.3509 0.0018 
231538_at 64776 C11orf1 chromosome 11 open reading frame 1 2.3463 0.0018 
218404_at 29887 SNX10 sorting nexin 10 2.3426 0.0017 
229744_at 6744 SSFA2 sperm specific antigen 2 2.2639 0.0018 
222834_s_at 55970 GNG12 guanine nucleotide binding protein (G protein), gamma 12 2.3355 0.0018 
212055_at 25941 C18orf10 chromosome 18 open reading frame 10 2.3564 0.0019 
236473_at 57545 CC2D2A coiled-coil and C2 domain containing 2A 2.1944 0.0019 
222734_at 10352 WARS2 tryptophanyl tRNA synthetase 2, mitochondrial 2.3083 0.0019 
201634_s_at 80777 CYB5B cytochrome b5 type B (outer mitochondrial membrane) 2.3037 0.0019 
201689_s_at 7163 TPD52 tumor protein D52 2.3188 0.002 
231764_at 54108 CHRAC1 chromatin accessibility complex 1 2.3608 0.002 
226276_at 153339 TMEM167A transmembrane protein 167A 2.3452 0.0019 
225400_at 116461 TSEN15 tRNA splicing endonuclease 15 homolog (S. cerevisiae) 2.3403 0.002 
222846_at 51762 RAB8B RAB8B, member RAS oncogene family 2.2115 0.0021 
207265_s_at 11015 KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 2.3432 0.0022 
214007_s_at 5756 TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 2.3483 0.0022 
200864_s_at 8766 RAB11A RAB11A, member RAS oncogene family 2.2929 0.0022 
1555758_a_at 1033 CDKN3 cyclin-dependent kinase inhibitor 3 2.3171 0.0023 
230413_s_at - - - 2.3422 0.0023 
202142_at 10920 COPS8 COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis) 2.3226 0.0022 
212529_at 124801 LSM12 LSM12 homolog (S. cerevisiae) 2.3342 0.0022 
221617_at 51616 TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa 2.3307 0.0022 
202919_at 25843 MOBKL3 MOB1, Mps One Binder kinase activator-like 3 (yeast) 2.3235 0.0023 
230122_at 8028 MLLT10 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 2.2765 0.0022 
201309_x_at 9315 C5orf13 chromosome 5 open reading frame 13 2.3372 0.0022 
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200902_at 9403 sept.15 15 kDa selenoprotein 2.3333 0.0022 
224650_at 114569 MAL2 mal, T-cell differentiation protein 2 2.2686 0.0022 
238675_x_at 91408 BTF3L4 basic transcription factor 3-like 4 2.3014 0.0022 
209274_s_at 81689 ISCA1 iron-sulfur cluster assembly 1 homolog (S. cerevisiae) 2.2945 0.0022 
225940_at 317649 EIF4E3 eukaryotic translation initiation factor 4E family member 3 2.309 0.0022 
222785_x_at 64776 C11orf1 chromosome 11 open reading frame 1 2.3185 0.0022 
218800_at 79644 SRD5A3 steroid 5 alpha-reductase 3 2.2531 0.0022 
226190_at - - - 2.3259 0.0022 
210802_s_at 27292 DIMT1L DIM1 dimethyladenosine transferase 1-like (S. cerevisiae) 2.3206 0.0022 
200704_at 9516 LITAF lipopolysaccharide-induced TNF factor 2.2715 0.0022 
235819_at - - - 2.3028 0.0023 
217971_at 8649 MAPKSP1 MAPK scaffold protein 1 2.2929 0.0023 
214762_at 534 ATP6V1G2 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 2.2451 0.0022 
200941_at 3281 HSBP1 heat shock factor binding protein 1 2.2808 0.0022 
224751_at 647087 PL-5283 PL-5283 protein 2.2971 0.0023 
227559_at 29078 NDUFAF4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 4 2.2543 0.0024 
214823_at 7754 ZNF204 zinc finger protein 204 pseudogene 2.3009 0.0024 
230376_at 2958 GTF2A2 general transcription factor IIA, 2, 12kDa 2.2238 0.0025 
227711_at 121355 GTSF1 gametocyte specific factor 1 2.3011 0.0026 
203858_s_at 1352 COX10 COX10 homolog, cytochrome c oxidase assembly protein, heme A: farnesyltransferase (yeast) 2.259 0.0026 
218668_s_at 57826 RAP2C RAP2C, member of RAS oncogene family 2.2599 0.0027 
238803_at 143279 HECTD2 HECT domain containing 2 2.2611 0.0027 
1552344_s_at 29883 CNOT7 CCR4-NOT transcription complex, subunit 7 2.2225 0.0027 
203799_at 9936 CD302 CD302 molecule 2.2926 0.0026 
224690_at 116151 C20orf108 chromosome 20 open reading frame 108 2.2278 0.0026 
225693_s_at 23261 CAMTA1 calmodulin binding transcription activator 1 2.2885 0.0027 
222679_s_at 54165 DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae) 2.1801 0.0027 
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218379_at 10179 RBM7 RNA binding motif protein 7 2.2759 0.0027 
211071_s_at 10962 MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 2.2826 0.0027 
1554868_s_at 57092 PCNP PEST proteolytic signal containing nuclear protein 2.2712 0.0027 
222466_s_at 28977 MRPL42 mitochondrial ribosomal protein L42 2.2833 0.0027 
212837_at 23172 FAM175B family with sequence similarity 175, member B 2.2444 0.0027 
214676_x_at 4584 MUC3A mucin 3A, cell surface associated 2.2061 0.0027 
210125_s_at 8815 BANF1 barrier to autointegration factor 1 2.2648 0.0027 
217989_at 51170 HSD17B11 hydroxysteroid (17-beta) dehydrogenase 11 2.2774 0.0027 
208025_s_at 8091 HMGA2 high mobility group AT-hook 2 2.2816 0.0027 
217827_s_at 51324 SPG21 spastic paraplegia 21 (autosomal recessive, Mast syndrome) 2.2627 0.0027 
202345_s_at 2171 FABP5 fatty acid binding protein 5 (psoriasis-associated) 2.2797 0.0027 
243237_at - - - 2.2026 0.0027 
218174_s_at 80195 C10orf57 chromosome 10 open reading frame 57 2.1884 0.0027 
225581_s_at 54534 MRPL50 mitochondrial ribosomal protein L50 2.2755 0.0027 
206928_at 7678 ZNF124 zinc finger protein 124 2.2214 0.0027 
236721_at 8846 ALKBH1 alkB, alkylation repair homolog 1 (E. coli) 2.2283 0.0028 
218583_s_at 54165 DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae) 2.2732 0.0028 
231530_s_at 64776 C11orf1 chromosome 11 open reading frame 1 2.2491 0.0028 
205184_at 2786 GNG4 guanine nucleotide binding protein (G protein), gamma 4 2.2518 0.0028 
211758_x_at 10190 TXNDC9 thioredoxin domain containing 9 2.2626 0.0028 
238465_at 133383 C5orf35 chromosome 5 open reading frame 35 2.2334 0.0028 
222637_at 51397 COMMD10 COMM domain containing 10 2.2746 0.0028 
218467_at 56984 PSMG2 proteasome (prosome, macropain) assembly chaperone 2 2.2648 0.0028 
218784_s_at 55776 C6orf64 chromosome 6 open reading frame 64 2.167 0.0028 
220198_s_at 56648 EIF5A2 eukaryotic translation initiation factor 5A2 2.2224 0.0028 
219288_at 57415 C3orf14 chromosome 3 open reading frame 14 2.2643 0.0028 
209404_s_at 51014 TMED7 transmembrane emp24 protein transport domain containing 7 2.2409 0.0029 
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230921_s_at - - - 2.2646 0.0029 
219210_s_at 51762 RAB8B RAB8B, member RAS oncogene family 2.2209 0.0029 
208819_at 4218 RAB8A RAB8A, member RAS oncogene family 2.235 0.0029 
228142_at 29796 UCRC ubiquinol-cytochrome c reductase complex (7.2 kD) 2.1925 0.0029 
218899_s_at 79870 BAALC brain and acute leukemia, cytoplasmic 2.0691 0.0029 
229145_at 119504 C10orf104 chromosome 10 open reading frame 104 2.1616 0.0029 
212371_at 51029 PPPDE1 PPPDE peptidase domain containing 1 2.1792 0.0029 
200794_x_at 9802 DAZAP2 DAZ associated protein 2 2.2288 0.003 
225228_at 128338 DRAM2 DNA-damage regulated autophagy modulator 2 2.1891 0.003 
218212_s_at 4338 MOCS2 molybdenum cofactor synthesis 2 2.2206 0.003 
1556736_at 1E+08 LOC100129858 hypothetical protein LOC100129858 2.1791 0.003 
226751_at 25927 CNRIP1 cannabinoid receptor interacting protein 1 2.2125 0.003 
217868_s_at 51108 METTL9 methyltransferase like 9 2.1829 0.0031 
235155_at 56898 BDH2 3-hydroxybutyrate dehydrogenase, type 2 2.139 0.0031 
202110_at 1349 COX7B cytochrome c oxidase subunit VIIb 2.2236 0.0032 
203065_s_at 857 CAV1 caveolin 1, caveolae protein, 22kDa 2.2225 0.0032 
1555765_a_at 2786 GNG4 guanine nucleotide binding protein (G protein), gamma 4 2.2159 0.0032 
227534_at 195827 C9orf21 chromosome 9 open reading frame 21 2.1725 0.0032 
224641_at 84248 FYTTD1 forty-two-three domain containing 1 2.2279 0.0031 
213263_s_at 5094 PCBP2 poly(rC) binding protein 2 2.2211 0.0032 
208745_at 10632 ATP5L ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G 2.1882 0.0033 
226220_at 51108 METTL9 methyltransferase like 9 2.1683 0.0034 
231102_at 54677 CROT carnitine O-octanoyltransferase 2.1467 0.0034 
212751_at 7334 UBE2N ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast) 2.1868 0.0034 
208770_s_at 1979 EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 2.2 0.0034 
235362_at 729970 LOC729970 similar to hCG2028352 2.1489 0.0034 
209771_x_at 1E+08 CD24 CD24 molecule 2.2053 0.0033 
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238574_at 92014 MCART1 mitochondrial carrier triple repeat 1 2.1481 0.0033 
224971_at 51263 MRPL30 mitochondrial ribosomal protein L30 2.2123 0.0034 
212281_s_at 27346 TMEM97 transmembrane protein 97 2.1893 0.0033 
232752_at - - - 2.1636 0.0035 
210186_s_at 2280 FKBP1A FK506 binding protein 1A, 12kDa 2.1893 0.0035 
224364_s_at 53938 PPIL3 peptidylprolyl isomerase (cyclophilin)-like 3 2.2062 0.0035 
201022_s_at 11034 DSTN destrin (actin depolymerizing factor) 2.1967 0.0034 
1552370_at 132321 C4orf33 chromosome 4 open reading frame 33 2.2061 0.0034 
204031_s_at 5094 PCBP2 poly(rC) binding protein 2 2.2006 0.0035 
228391_at 285440 CYP4V2 cytochrome P450, family 4, subfamily V, polypeptide 2 2.1564 0.0034 
201690_s_at 7163 TPD52 tumor protein D52 2.1907 0.0035 
223551_at 5570 PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta 2.1804 0.0035 
200823_x_at 6159 RPL29 ribosomal protein L29 2.194 0.0035 
224693_at 116151 C20orf108 chromosome 20 open reading frame 108 2.1716 0.0035 
202165_at 5504 PPP1R2 protein phosphatase 1, regulatory (inhibitor) subunit 2 2.1764 0.0036 
203008_x_at 10190 TXNDC9 thioredoxin domain containing 9 2.1776 0.0035 
201380_at 10491 CRTAP cartilage associated protein 2.1455 0.0035 
212294_at 55970 GNG12 guanine nucleotide binding protein (G protein), gamma 12 2.187 0.0035 
235296_at 56648 EIF5A2 eukaryotic translation initiation factor 5A2 2.1455 0.0036 
214812_s_at 55233 MOBKL1B MOB1, Mps One Binder kinase activator-like 1B (yeast) 2.1746 0.0036 
220199_s_at 64853 AIDA axin interactor, dorsalization associated 2.1624 0.0036 
231130_at 51661 FKBP7 FK506 binding protein 7 2.1859 0.0036 
209130_at 8773 SNAP23 synaptosomal-associated protein, 23kDa 2.1708 0.0036 
206440_at 8825 LIN7A lin-7 homolog A (C. elegans) 2.1799 0.0035 
238164_at 9712 USP6NL USP6 N-terminal like 2.1157 0.0035 
208762_at 7341 SUMO1 SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae) 2.171 0.0035 
1558819_at 1E+08 - - 2.0422 0.0035 
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230787_at - - - 2.125 0.0035 
209806_at 85236 HIST1H2BK histone cluster 1, H2bk 2.1848 0.0036 
201297_s_at 55233 MOBKL1B MOB1, Mps One Binder kinase activator-like 1B (yeast) 2.1879 0.0035 
1561894_at 653739 LOC653739 hypothetical protein LOC653739 2.1072 0.0036 
225125_at 93380 MMGT1 membrane magnesium transporter 1 2.1442 0.0036 
224436_s_at 25934 NIPSNAP3A nipsnap homolog 3A (C. elegans) 2.1787 0.0037 
216379_x_at 1E+08 CD24 CD24 molecule 2.1797 0.0038 
204675_at 6715 SRD5A1 steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) 2.0482 0.0038 
217783_s_at 51646 YPEL5 yippee-like 5 (Drosophila) 2.1675 0.0038 
201649_at 9246 UBE2L6 ubiquitin-conjugating enzyme E2L 6 2.1236 0.0038 
222531_s_at 55745 MUDENG MU-2/AP1M2 domain containing, death-inducing 2.1275 0.0038 
238126_at - - - 2.0119 0.0038 
224752_at 647087 PL-5283 PL-5283 protein 2.149 0.004 
202732_at 11142 PKIG protein kinase (cAMP-dependent, catalytic) inhibitor gamma 2.0765 0.004 
201120_s_at 10857 PGRMC1 progesterone receptor membrane component 1 2.0931 0.004 
242328_at 115827 RAB3C RAB3C, member RAS oncogene family 2.0892 0.0039 
213061_s_at 123803 NTAN1 N-terminal asparagine amidase 2.126 0.0039 
201435_s_at 1977 EIF4E eukaryotic translation initiation factor 4E 2.1593 0.0039 
211727_s_at 1353 COX11 COX11 homolog, cytochrome c oxidase assembly protein (yeast) 2.1018 0.0039 
216241_s_at 6917 TCEA1 transcription elongation factor A (SII), 1 2.1297 0.004 
227295_at 121457 IKIP IKK interacting protein 2.1537 0.004 
238461_at 317649 EIF4E3 eukaryotic translation initiation factor 4E family member 3 2.1261 0.0041 
202903_at 23658 LSM5 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) 2.0956 0.004 
207437_at 4857 NOVA1 neuro-oncological ventral antigen 1 2.1286 0.0041 
214008_at 5756 TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 2.1541 0.004 
202141_s_at 10920 COPS8 COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis) 2.1228 0.004 
205741_s_at 1837 DTNA dystrobrevin, alpha 2.0805 0.0041 
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201001_s_at 7335 UBE2V1 ubiquitin-conjugating enzyme E2 variant 1 2.1381 0.0041 
201302_at 307 ANXA4 annexin A4 2.0861 0.0041 
208769_at 1979 EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 2.0739 0.0041 
218250_s_at 29883 CNOT7 CCR4-NOT transcription complex, subunit 7 2.0942 0.0043 
230655_at - - - 2.1301 0.0043 
221618_s_at 51616 TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa 2.0533 0.0046 
212449_s_at 10434 LYPLA1 lysophospholipase I 2.1111 0.0047 
224731_at 3146 HMGB1 high-mobility group box 1 2.1443 0.0049 
212590_at 22800 RRAS2 related RAS viral (r-ras) oncogene homolog 2 2.107 0.0048 
217773_s_at 4697 NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa 2.1214 0.0049 
244114_x_at - - - 2.1216 0.0049 
217819_at 51125 GOLGA7 golgi autoantigen, golgin subfamily a, 7 2.0837 0.0049 
230264_s_at 8905 AP1S2 adaptor-related protein complex 1, sigma 2 subunit 2.0904 0.0051 
226529_at 54664 TMEM106B transmembrane protein 106B 2.0986 0.0051 
229746_x_at - - - 2.1196 0.0052 
208655_at - - - 2.0777 0.0051 
227165_at 221150 SKA3 spindle and kinetochore associated complex subunit 3 2.1129 0.0051 
1555501_s_at 51319 RSRC1 arginine/serine-rich coiled-coil 1 2.1163 0.0053 
222437_s_at 51652 VPS24 vacuolar protein sorting 24 homolog (S. cerevisiae) 2.0825 0.0054 
241443_at - - - 2.066 0.0054 
202334_s_at 7320 UBE2B ubiquitin-conjugating enzyme E2B (RAD6 homolog) 2.0593 0.0054 
212833_at 91137 SLC25A46 solute carrier family 25, member 46 2.0946 0.0055 
227932_at 10425 ARIH2 ariadne homolog 2 (Drosophila) 2.0662 0.0055 
226745_at 285440 CYP4V2 cytochrome P450, family 4, subfamily V, polypeptide 2 2.0795 0.0056 
213846_at 1350 COX7C cytochrome c oxidase subunit VIIc 2.0832 0.0055 
202166_s_at 5504 PPP1R2 protein phosphatase 1, regulatory (inhibitor) subunit 2 2.0291 0.0057 
225941_at 317649 EIF4E3 eukaryotic translation initiation factor 4E family member 3 2.0803 0.0057 
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203466_at 4358 MPV17 MpV17 mitochondrial inner membrane protein 2.0746 0.0057 
226278_at 258010 SVIP small VCP/p97-interacting protein 2.0334 0.0058 
214022_s_at 8519 IFITM1 interferon induced transmembrane protein 1 (9-27) 2.1031 0.0058 
204612_at 5569 PKIA protein kinase (cAMP-dependent, catalytic) inhibitor alpha 2.0835 0.0058 
205621_at 8846 ALKBH1 alkB, alkylation repair homolog 1 (E. coli) 2.0679 0.0059 
206113_s_at 5868 RAB5A RAB5A, member RAS oncogene family 2.0838 0.006 
226686_at 493856 CISD2 CDGSH iron sulfur domain 2 2.0634 0.0059 
203207_s_at 9650 MTFR1 mitochondrial fission regulator 1 2.0536 0.006 
200922_at 10945 KDELR1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 2.0612 0.0061 
219875_s_at 51029 PPPDE1 PPPDE peptidase domain containing 1 2.0127 0.0062 
224664_at 119504 C10orf104 chromosome 10 open reading frame 104 2.0505 0.0062 
218643_s_at 9419 CRIPT cysteine-rich PDZ-binding protein 2.0697 0.0062 
209089_at 5868 RAB5A RAB5A, member RAS oncogene family 2.0811 0.0062 
225036_at 6461 SHB Src homology 2 domain containing adaptor protein B 2.0829 0.0062 
214119_s_at 2280 FKBP1A FK506 binding protein 1A, 12kDa 2.064 0.0062 
1557411_s_at 203427 SLC25A43 solute carrier family 25, member 43 2.0656 0.0062 
219029_at 64417 C5orf28 chromosome 5 open reading frame 28 2.0366 0.0064 
1556236_at - - - 2.0739 0.0064 
200067_x_at 8724 SNX3 sorting nexin 3 2.0621 0.0064 
225939_at 317649 EIF4E3 eukaryotic translation initiation factor 4E family member 3 2.0223 0.0065 
218420_s_at 80209 C13orf23 chromosome 13 open reading frame 23 2.0387 0.0064 
238599_at 134728 IRAK1BP1 interleukin-1 receptor-associated kinase 1 binding protein 1 2.0212 0.0064 
201399_s_at 23471 TRAM1 translocation associated membrane protein 1 2.0164 0.0064 
236204_at - - - 2.0542 0.0064 
217837_s_at 51652 VPS24 vacuolar protein sorting 24 homolog (S. cerevisiae) 2.0437 0.0064 
235010_at 729013 LOC729013 hypothetical protein LOC729013 2.0267 0.0064 
244523_at 23531 MMD monocyte to macrophage differentiation-associated 2.0478 0.0065 
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209065_at 7381 UQCRB ubiquinol-cytochrome c reductase binding protein 2.0289 0.0065 
218010_x_at 79144 PPDPF pancreatic progenitor cell differentiation and proliferation factor homolog (zebrafish) 2.0758 0.0064 
218163_at 28985 MCTS1 malignant T cell amplified sequence 1 2.0614 0.0065 
201980_s_at 6251 RSU1 Ras suppressor protein 1 2.0709 0.0065 
203561_at 2212 FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) 2.0503 0.0066 
213930_at - - - 2.0026 0.0066 
226159_at 285636 C5orf51 chromosome 5 open reading frame 51 2.0297 0.0065 
231401_s_at - - - 2.0323 0.0066 
224577_at 57222 ERGIC1 endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1 2.0135 0.0067 
204420_at 8061 FOSL1 FOS-like antigen 1 2.0428 0.0068 
200986_at 710 SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 2.0548 0.0068 
203897_at 57149 LYRM1 LYR motif containing 1 2.0101 0.0069 
266_s_at 1E+08 CD24 CD24 molecule 2.0353 0.0072 
206272_at 5867 RAB4A RAB4A, member RAS oncogene family 2.0011 0.0075 
226831_at 91137 SLC25A46 solute carrier family 25, member 46 2.0016 0.0076 
235470_at - - - 2.0033 0.0077 
201653_at 10175 CNIH cornichon homolog (Drosophila) 2.0187 0.0078 
217909_s_at 6945 MLX MAX-like protein X 2.0074 0.0079 
213882_at 83941 TM2D1 TM2 domain containing 1 2.0145 0.0078 
238935_at 51065 RPS27L ribosomal protein S27-like 2.0046 0.0079 
202168_at 6880 TAF9 TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa 2.0091 0.0083 
202829_s_at 6845 VAMP7 vesicle-associated membrane protein 7 2.0062 0.0084 
203300_x_at 8905 AP1S2 adaptor-related protein complex 1, sigma 2 subunit 2.0004 0.0083 
208905_at 54205 CYCS cytochrome c, somatic 2.0106 0.0085 
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Epilogue 
 
Although the hallmarks of cancer seem to be unified among all cancer types, 
regardless of the tissue of origin, there is an enormous heterogeneity not only between 
different tumors, but also at the cellular level within a given tumor. The discovery of 
cancer stem cells has opened a new field of research and the appearance of CSC in 
various tumor types starts to be considered as a new hallmark of cancer. Despite the 
fact that CSC from different tumors can be isolated with the same set of cell surface 
markers, it seems that there is no unified profile of CSC. As in the case of other 
cancer hallmarks, like proliferation, the observations from different cancer cell types 
point to the same functional phenotype that can be however underlined by an array of 
biological alterations. Thus, understanding the details of molecular biology governing 
CSC in different tumor types would be crucial for finding new therapeutic solutions to 
eliminate those cells.  
Cancer stem cells can be isolated with cell surface markers, of often uncertain 
significance for the cellular biology. However, “stemness” of a given cancer cell can 
be determined only functionally, in spherogenic, tumorigenic and differentiation 
assays. Thus, finding specific CSC markers that could also serve as therapeutic targets 
requires careful investigation of their role in those cells. In this work a new function 
of well-described CSC marker CD44 has been found. Although nuclear localization of 
the full-length CD44 and its role in transcription does not seem to be dependent on 
cell tumorigenicity, it could well be that this function is also important for the CSC. 
Therefore, a new feature of multifunctional CD44 presented in this study might help 
to establish why many CSC from different tumors express this protein. 
The second part of the present work resulted in identification of new 
biological feature of CSC. The discovery of Imp2 as a regulator of OxPhos in CSC 
has shed new light on metabolism of those cells. OxPhos dependence of CSC 
underlines another important functional difference between those cells and the bulk of 
a tumor and at the same time couples them to normal stem cells, which also use 
OxPhos as the major energy producing pathway. This new metabolic difference 
between CSC and their more differentiated counterparts can lead to identification of 
novel markers or therapeutical targets.  
Summarizing, the two projects described in this work present two different 
approaches – a study of a well known CSC marker to uncover its new functions and 
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an attempt to find a new function for a protein highly expressed by CSC. Both types 
of investigation can help to gather new data crucial for understanding the biology of 
CSC. 
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